|
G
|
A2ml1
|
alpha-2-macroglobulin-like 1
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of OVOS2 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 4:163,501,210...163,543,419
Ensembl chr 4:163,501,585...163,543,506
|
|
G
|
Abat
|
4-aminobutyrate aminotransferase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ABAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474
|
|
G
|
Abca5
|
ATP binding cassette subfamily A member 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA panobinostat results in decreased expression of ABCA5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:95,739,610...95,808,633
Ensembl chr10:95,739,610...95,808,424
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abhd14a
|
abhydrolase domain containing 14A
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ABHD14A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:115,957,853...115,965,697
Ensembl chr 8:115,957,858...115,965,697
|
|
G
|
Abl1
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846
|
|
G
|
Acad11
|
acyl-CoA dehydrogenase family, member 11
|
increases expression
|
ISO
|
panobinostat results in increased expression of ACAD11 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 8:113,560,142...113,625,346
Ensembl chr 8:113,560,196...113,625,352
|
|
G
|
Ackr3
|
atypical chemokine receptor 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ACKR3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214
|
|
G
|
Acp3
|
acid phosphatase 3
|
increases expression multiple interactions
|
ISO
|
Panobinostat results in increased expression of ACP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:113,785,032...113,833,033
|
|
G
|
Acsl1
|
acyl-CoA synthetase long-chain family member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA panobinostat results in increased expression of ACSL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023
|
|
G
|
Acsm3
|
acyl-CoA synthetase medium-chain family member 3
|
increases expression
|
ISO
|
panobinostat results in increased expression of ACSM3 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of ACTA2 mRNA
|
CTD |
PMID:30481203 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ada
|
adenosine deaminase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA panobinostat results in decreased expression of ADA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293
|
|
G
|
Adam12
|
ADAM metallopeptidase domain 12
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ADAM12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552
|
|
G
|
Adam22
|
ADAM metallopeptidase domain 22
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA panobinostat results in decreased expression of ADAM22 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:26,670,984...26,925,843
Ensembl chr 4:26,671,112...26,925,843
|
|
G
|
Adam28
|
ADAM metallopeptidase domain 28
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA panobinostat results in increased expression of ADAM28 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:50,184,286...50,250,605
Ensembl chr15:50,127,516...50,250,526
|
|
G
|
Adamts15
|
ADAM metallopeptidase with thrombospondin type 1 motif, 15
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA panobinostat results in increased expression of ADAMTS15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446
|
|
G
|
Adamts17
|
ADAM metallopeptidase with thrombospondin type 1 motif, 17
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:129,856,062...130,178,430
Ensembl chr 1:129,856,074...130,176,844
|
|
G
|
Adamts19
|
ADAM metallopeptidase with thrombospondin type 1 motif, 19
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA panobinostat results in increased expression of ADAMTS19 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:54,545,357...54,729,184
Ensembl chr18:54,545,357...54,729,181
|
|
G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ADCYAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383
|
|
G
|
Adcyap1r1
|
ADCYAP receptor type I
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA panobinostat results in increased expression of ADCYAP1R1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973
|
|
G
|
Adgrg1
|
adhesion G protein-coupled receptor G1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA panobinostat results in decreased expression of ADGRG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124
|
|
G
|
Adgrg6
|
adhesion G protein-coupled receptor G6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023
|
|
G
|
Adgrl3
|
adhesion G protein-coupled receptor L3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ADGRL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418
|
|
G
|
Adgrv1
|
adhesion G protein-coupled receptor V1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA panobinostat results in decreased expression of ADGRV1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:13,067,149...13,647,407
Ensembl chr 2:13,067,150...13,647,372
|
|
G
|
Adra2a
|
adrenoceptor alpha 2A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871
|
|
G
|
Afap1l1
|
actin filament associated protein 1-like 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of AFAP1L1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:55,183,786...55,244,174
Ensembl chr18:57,454,121...57,514,480
|
|
G
|
Ahnak
|
AHNAK nucleoprotein
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of AHNAK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675
|
|
G
|
Ajap1
|
adherens junctions associated protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA panobinostat results in increased expression of AJAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:169,190,477...169,302,938
Ensembl chr 5:169,190,477...169,304,515
|
|
G
|
Akap12
|
A-kinase anchoring protein 12
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA panobinostat results in decreased expression of AKAP12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein
|
CTD |
PMID:18445700 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alcam
|
activated leukocyte cell adhesion molecule
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ALCAM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876
|
|
G
|
Aldh1a2
|
aldehyde dehydrogenase 1 family, member A2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ALDH1A2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883
|
|
G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ALDH1A3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
G
|
Aldh1l2
|
aldehyde dehydrogenase 1 family, member L2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ALDH1L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398
|
|
G
|
Alkal2
|
ALK and LTK ligand 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA panobinostat results in increased expression of ALKAL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:53,223,204...53,232,794
Ensembl chr 6:53,223,341...53,233,011
|
|
G
|
Alx1
|
ALX homeobox 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ALX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:40,044,185...40,063,778
Ensembl chr 7:40,033,676...40,063,778
|
|
G
|
Amer2
|
APC membrane recruitment protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of AMER2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:34,525,352...34,535,660
Ensembl chr15:38,701,657...38,705,633
|
|
G
|
Amigo2
|
adhesion molecule with Ig like domain 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA panobinostat results in increased expression of AMIGO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218
|
|
G
|
Ang
|
angiogenin
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106
|
|
G
|
Angpt1
|
angiopoietin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA panobinostat results in increased expression of ANGPT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696
|
|
G
|
Angpt2
|
angiopoietin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA panobinostat results in increased expression of ANGPT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239
|
|
G
|
Ankh
|
ANKH inorganic pyrophosphate transport regulator
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA panobinostat results in increased expression of ANKH mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699
|
|
G
|
Ankrd1
|
ankyrin repeat domain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA panobinostat results in increased expression of ANKRD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751
|
|
G
|
Ankrd22
|
ankyrin repeat domain 22
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:241,052,235...241,083,737
Ensembl chr 1:241,052,237...241,105,559
|
|
G
|
Anks1b
|
ankyrin repeat and sterile alpha motif domain containing 1B
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:26,201,240...27,364,943
|
|
G
|
Ano3
|
anoctamin 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:117,690,242...118,004,695
Ensembl chr 3:117,692,103...118,004,675
|
|
G
|
Anxa1
|
annexin A1
|
increases expression
|
ISO
|
panobinostat results in increased expression of ANXA1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831
|
|
G
|
Anxa2
|
annexin A2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ANXA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631
|
|
G
|
Anxa3
|
annexin A3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA panobinostat results in increased expression of ANXA3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849
|
|
G
|
Anxa9
|
annexin A9
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560
|
|
G
|
Aox1
|
aldehyde oxidase 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of AOX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980
|
|
G
|
Ap1m2
|
adaptor related protein complex 1 subunit mu 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA panobinostat results in increased expression of AP1M2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:28,114,748...28,132,767
Ensembl chr 8:28,114,748...28,132,642
|
|
G
|
Ap5s1
|
adaptor related protein complex 5 subunit sigma 1
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of AP5S1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:138,882,634...138,888,899
|
|
G
|
Apela
|
apelin receptor early endogenous ligand
|
increases expression
|
ISO
|
Panobinostat results in increased expression of APELA mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr16:29,460,855...29,469,962
Ensembl chr16:29,460,812...29,469,955
|
|
G
|
Arap2
|
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ARAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:50,921,323...51,120,972
Ensembl chr14:50,921,713...51,120,962
|
|
G
|
Arfgef3
|
ARFGEF family member 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA panobinostat results in decreased expression of ARFGEF3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:15,058,579...15,223,742
|
|
G
|
Arhgap15
|
Rho GTPase activating protein 15
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA panobinostat results in decreased expression of ARHGAP15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:48,382,945...49,002,213
Ensembl chr 3:48,382,904...49,011,378
|
|
G
|
Arhgap18
|
Rho GTPase activating protein 18
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA panobinostat results in increased expression of ARHGAP18 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670
|
|
G
|
Arhgap24
|
Rho GTPase activating protein 24
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950
|
|
G
|
Arhgap31
|
Rho GTPase activating protein 31
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076
|
|
G
|
Arhgap5
|
Rho GTPase activating protein 5
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ARHGAP5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636
|
|
G
|
Arhgap6
|
Rho GTPase activating protein 6
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ARHGAP6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:28,525,912...29,062,344
Ensembl chr X:28,525,917...29,061,244
|
|
G
|
Arid2
|
AT-rich interaction domain 2
|
affects expression multiple interactions
|
ISO
|
panobinostat affects the expression of ARID2 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187
|
|
G
|
Arid5b
|
AT-rich interaction domain 5B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA panobinostat results in increased expression of ARID5B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686
|
|
G
|
Armh4
|
armadillo-like helical domain containing 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA panobinostat results in decreased expression of ARMH4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:22,975,895...23,076,986
Ensembl chr15:25,455,297...25,556,534
|
|
G
|
Arnt2
|
aryl hydrocarbon receptor nuclear translocator 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ARNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997
|
|
G
|
Arrb1
|
arrestin, beta 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ARRB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859
|
|
G
|
Arx
|
aristaless related homeobox
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ARX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:62,010,097...62,022,009
Ensembl chr X:62,010,097...62,022,002
|
|
G
|
As3mt
|
arsenite methyltransferase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:255,536,879...255,569,245
Ensembl chr 1:255,537,109...255,569,249
|
|
G
|
Asb9
|
ankyrin repeat and SOCS box-containing 9
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:33,588,484...33,633,285
Ensembl chr X:33,588,484...33,624,397
|
|
G
|
Ascl1
|
achaete-scute family bHLH transcription factor 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231
|
|
G
|
Asic1
|
acid sensing ion channel subunit 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832
|
|
G
|
Asns
|
asparagine synthetase (glutamine-hydrolyzing)
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ASNS mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050
|
|
G
|
Ass1
|
argininosuccinate synthase 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ASS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627
|
|
G
|
Astn1
|
astrotactin 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ASTN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:73,070,754...73,388,902
Ensembl chr13:73,071,267...73,388,895
|
|
G
|
Astn2
|
astrotactin 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ASTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:83,772,988...84,759,439
Ensembl chr 5:83,773,633...84,759,485
|
|
G
|
Atf3
|
activating transcription factor 3
|
increases expression
|
ISO
|
panobinostat results in increased expression of ATF3 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
G
|
Atp13a4
|
ATPase 13A4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr11:84,727,014...84,864,747
Ensembl chr11:84,731,041...84,864,747
|
|
G
|
Atp23
|
ATP23 metallopeptidase and ATP synthase assembly factor homolog
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ATP23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:64,600,100...64,615,240
Ensembl chr 7:64,600,100...64,615,392
|
|
G
|
Atp2c2
|
ATPase secretory pathway Ca2+ transporting 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA panobinostat results in increased expression of ATP2C2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996
|
|
G
|
Atp6v0a2
|
ATPase H+ transporting V0 subunit a2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA panobinostat results in decreased expression of ATP6V0A2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:37,608,211...37,640,860
Ensembl chr12:37,472,813...37,640,860
|
|
G
|
Atp6v0a4
|
ATPase H+ transporting V0 subunit a4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA panobinostat results in increased expression of ATP6V0A4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:67,727,145...67,809,092
Ensembl chr 4:67,727,145...67,809,092
|
|
G
|
Atp6v0d2
|
ATPase H+ transporting V0 subunit D2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA panobinostat results in increased expression of ATP6V0D2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245
|
|
G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA panobinostat results in increased expression of ATP8B1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027
|
|
G
|
Atp8b3
|
ATPase phospholipid transporting 8B3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA panobinostat results in increased expression of ATP8B3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,826,275...9,846,195
|
|
G
|
Atp9a
|
ATPase phospholipid transporting 9A (putative)
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA panobinostat results in decreased expression of ATP9A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:177,779,203...177,886,431
Ensembl chr 3:177,779,203...178,023,661
|
|
G
|
Axin2
|
axin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA panobinostat results in increased expression of AXIN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575
|
|
G
|
B3gnt7
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA panobinostat results in increased expression of B3GNT7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:94,404,135...94,408,147
|
|
G
|
Bace2
|
beta-secretase 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BACE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:50,176,852...50,258,948
Ensembl chr11:50,176,621...50,259,008
|
|
G
|
Bag2
|
BAG cochaperone 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA panobinostat results in increased expression of BAG2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752
|
|
G
|
Bag5
|
BAG cochaperone 5
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 6:136,589,623...136,593,278
Ensembl chr 6:136,584,741...136,598,492
|
|
G
|
Bambi
|
BMP and activin membrane-bound inhibitor
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BAMBI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247
|
|
G
|
Batf3
|
basic leucine zipper ATF-like transcription factor 3
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]
|
CTD |
PMID:18445700 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Baz1a
|
bromodomain adjacent to zinc finger domain, 1A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA panobinostat results in increased expression of BAZ1A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:78,124,872...78,247,672
Ensembl chr 6:78,124,872...78,247,648
|
|
G
|
Bcl11a
|
BCL11 transcription factor A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BCL11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
affects expression decreases expression multiple interactions
|
ISO
|
panobinostat affects the expression of BCL2 mRNA panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA]
|
CTD |
PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l11
|
Bcl2-like 11
|
multiple interactions decreases expression increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] panobinostat results in decreased expression of BCL2L11 mRNA panobinostat results in increased expression of BCL2L11 protein
|
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
G
|
Begain
|
brain-enriched guanylate kinase-associated
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA panobinostat results in decreased expression of BEGAIN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:133,708,010...133,744,264
Ensembl chr 6:133,708,007...133,744,526
|
|
G
|
Best4
|
bestrophin 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA panobinostat results in decreased expression of BEST4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:135,858,774...135,865,624
Ensembl chr 5:135,860,018...135,863,707
|
|
G
|
Bex5l1
|
brain expressed X-linked 5 like 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA panobinostat results in increased expression of BEX5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:119,181,370...119,202,904
|
|
G
|
Bhlhe40
|
basic helix-loop-helix family, member e40
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BHLHE40 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783
|
|
G
|
Bhlhe41
|
basic helix-loop-helix family, member e41
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of BIRC5 mRNA
|
CTD |
PMID:30481203 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bmal2
|
basic helix-loop-helix ARNT like 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of BMAL2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 4:181,429,097...181,478,384
Ensembl chr 4:181,430,159...181,478,382
|
|
G
|
Bmf
|
Bcl2 modifying factor
|
increases expression
|
ISO
|
Panobinostat results in increased expression of BMF mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258
|
|
G
|
Bmp2
|
bone morphogenetic protein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA panobinostat results in increased expression of BMP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760
|
|
G
|
Bmp4
|
bone morphogenetic protein 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA panobinostat results in increased expression of BMP4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172
|
|
G
|
Bmp5
|
bone morphogenetic protein 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA panobinostat results in increased expression of BMP5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189
|
|
G
|
Bmp7
|
bone morphogenetic protein 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA panobinostat results in increased expression of BMP7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137
|
|
G
|
Bmper
|
BMP-binding endothelial regulator
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA panobinostat results in increased expression of BMPER mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359
|
|
G
|
Bmpr1b
|
bone morphogenetic protein receptor type 1B
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311
|
|
G
|
Bnc2
|
basonuclin zinc finger protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BNC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428
|
|
G
|
Bnipl
|
BCL2 interacting protein like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA panobinostat results in increased expression of BNIPL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:185,507,591...185,519,415
Ensembl chr 2:185,507,593...185,517,582
|
|
G
|
Boc
|
BOC cell adhesion associated, oncogene regulated
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA panobinostat results in increased expression of BOC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:69,628,703...69,704,009
Ensembl chr11:69,628,660...69,704,004
|
|
G
|
Bri3bp
|
Bri3 binding protein
|
increases expression
|
ISO
|
panobinostat results in increased expression of BRI3BP mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr12:31,176,742...31,188,563
Ensembl chr12:36,838,098...36,849,919
|
|
G
|
Brinp1
|
BMP/retinoic acid inducible neural specific 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BRINP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256
|
|
G
|
Brip1
|
BRCA1 interacting DNA helicase 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206
|
|
G
|
Bspry
|
B-box and SPRY domain containing
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of BSPRY mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154
|
|
G
|
C11h3orf52
|
similar to human chromosome 3 open reading frame 52
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of C3ORF52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:55,166,986...55,192,273
Ensembl chr11:68,629,570...68,654,868
|
|
G
|
C13h1orf53
|
similar to human chromosome 1 open reading frame 53
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA panobinostat results in decreased expression of C1ORF53 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:50,413,785...50,418,974
Ensembl chr13:52,965,244...52,970,607
|
|
G
|
C19h16orf87
|
similar to human chromosome 16 open reading frame 87
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr19:21,626,390...21,653,869
Ensembl chr19:37,799,799...37,827,452
|
|
G
|
C1galt1
|
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA panobinostat results in increased expression of C1GALT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:36,894,488...36,932,441
|
|
G
|
C1h19orf33
|
similar to human chromosome 19 open reading frame 33
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA Panobinostat results in increased expression of C19ORF33 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:93,677,305...93,678,141
Ensembl chr 1:93,677,305...93,678,141
|
|
G
|
C1qtnf4
|
C1q and TNF related 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA panobinostat results in decreased expression of C1QTNF4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:97,310,220...97,328,818
Ensembl chr 3:97,327,670...97,342,587
|
|
G
|
C2cd2
|
C2 calcium-dependent domain containing 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA panobinostat results in decreased expression of C2CD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016
|
|
G
|
C2h3orf33
|
similar to human chromosome 3 open reading frame 33
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of C3ORF33 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:150,522,758...150,554,007
Ensembl chr 2:150,530,231...150,554,055
|
|
G
|
C3
|
complement C3
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339
|
|
G
|
C3h11orf96
|
similar to human chromosome 11 open reading frame 96
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA panobinostat results in increased expression of C11ORF96 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:100,351,199...100,378,346
|
|
G
|
C4h2orf68
|
similar to human chromosome 2 open reading frame 68
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of C2ORF68 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:105,960,751...105,966,508
|
|
G
|
C5h8orf34
|
similar to human chromosome 8 open reading frame 34
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA panobinostat results in increased expression of C8ORF34 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:12,021,007...12,559,772
|
|
G
|
C7h12orf56
|
similar to human chromosome 12 open reading frame 56
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of C12ORF56 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:59,055,283...59,106,900
Ensembl chr 7:59,056,310...59,106,407
|
|
G
|
C8h11orf52
|
similar to human chromosome 11 open reading frame 52
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:59,977,717...59,984,706
Ensembl chr 8:59,976,623...59,990,901
|
|
G
|
C9h6orf141
|
similar to human chromosome 6 open reading frame 141
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of C6ORF141 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:27,521,466...27,525,644
|
|
G
|
Ca12
|
carbonic anhydrase 12
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CA12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465
|
|
G
|
Ca13
|
carbonic anhydrase 13
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:88,649,625...88,680,763
|
|
G
|
Ca4
|
carbonic anhydrase 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916
|
|
G
|
Ca8
|
carbonic anhydrase 8
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:26,102,813...26,199,796
|
|
G
|
Cacna2d1
|
calcium voltage-gated channel auxiliary subunit alpha2delta 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CACNA2D1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147
|
|
G
|
Cacnb2
|
calcium voltage-gated channel auxiliary subunit beta 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CACNB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:82,473,097...82,818,564
Ensembl chr17:82,473,129...82,818,564
|
|
G
|
Cadm4
|
cell adhesion molecule 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CADM4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:80,075,163...80,097,423
Ensembl chr 1:89,202,554...89,225,345
|
|
G
|
Calb2
|
calbindin 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CALB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952
|
|
G
|
Calca
|
calcitonin-related polypeptide alpha
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CALCA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
G
|
Capn6
|
calpain 6
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CAPN6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein
|
CTD |
PMID:22923501 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein] panobinostat results in increased expression of CASP8 mRNA
|
CTD |
PMID:21791302 PMID:22923501 PMID:26272509 PMID:27188386 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein
|
CTD |
PMID:22923501 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cblc
|
Cbl proto-oncogene C
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CBLC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709
|
|
G
|
Cc2d2a
|
coiled-coil and C2 domain containing 2A
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331
|
|
G
|
Ccdc136
|
coiled-coil domain containing 136
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CCDC136 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:58,963,196...58,992,962
Ensembl chr 4:58,962,908...58,992,975
|
|
G
|
Ccdc177
|
coiled-coil domain containing 177
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CCDC177 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:100,404,526...100,411,112
Ensembl chr 6:106,134,333...106,144,441
|
|
G
|
Ccdc69
|
coiled-coil domain containing 69
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA panobinostat results in increased expression of CCDC69 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:39,673,984...39,701,080
Ensembl chr10:39,673,985...39,700,579
|
|
G
|
Cckbr
|
cholecystokinin B receptor
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CCKBR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745
|
|
G
|
Ccl26
|
C-C motif chemokine ligand 26
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CCL26 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:26,745,972...26,750,924
|
|
G
|
Ccn3
|
cellular communication network factor 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581
|
|
G
|
Ccng2
|
cyclin G2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CCNG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206
|
|
G
|
Ccnt2
|
cyclin T2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CCNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:41,804,007...41,845,641
Ensembl chr13:41,804,046...41,844,488
|
|
G
|
Cd200
|
Cd200 molecule
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569
|
|
G
|
Cd24
|
CD24 molecule
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA panobinostat results in increased expression of CD24 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785
|
|
G
|
Cd274
|
CD274 molecule
|
increases expression
|
ISO
|
Panobinostat results in increased expression of CD274 protein
|
CTD |
PMID:26775640 |
|
NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951
|
|
G
|
Cd44
|
CD44 molecule
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CD44 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424
|
|
G
|
Cd52
|
CD52 molecule
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CD52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086
|
|
G
|
Cd55
|
CD55 molecule (Cromer blood group)
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA panobinostat results in increased expression of CD55 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107
|
|
G
|
Cd74
|
CD74 molecule
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA panobinostat results in increased expression of CD74 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410
|
|
G
|
Cd9
|
CD9 molecule
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA panobinostat results in increased expression of CD9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444
|
|
G
|
Cdc42ep3
|
CDC42 effector protein 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA panobinostat results in decreased expression of CDC42EP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540
|
|
G
|
Cdc42ep5
|
CDC42 effector protein 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA panobinostat results in increased expression of CDC42EP5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:70,035,921...70,038,990
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA panobinostat results in increased expression of CDH1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh10
|
cadherin 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA panobinostat results in increased expression of CDH10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332
|
|
G
|
Cdh18
|
cadherin 18
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CDH18 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:74,548,681...75,550,720
Ensembl chr 2:75,075,595...75,550,720
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA panobinostat results in decreased expression of CDH2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdh3
|
cadherin 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CDH3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257
|
|
G
|
Cdh8
|
cadherin 8
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CDH8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:5,494,552...5,901,950
Ensembl chr19:5,500,221...5,902,627
|
|
G
|
Cdk19
|
cyclin-dependent kinase 19
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr20:45,324,911...45,465,121
Ensembl chr20:45,324,862...45,465,121
|
|
G
|
Cdk5r1
|
cyclin-dependent kinase 5 regulatory subunit 1
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of CDK5R1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272
|
|
G
|
Cdk6
|
cyclin-dependent kinase 6
|
multiple interactions increases expression
|
ISO
|
[(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA panobinostat results in increased expression of CDK6 mRNA
|
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
panobinostat results in increased expression of CDKN1A protein
|
CTD |
PMID:18445700 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
increases expression
|
ISO
|
panobinostat results in increased expression of CDKN1B protein
|
CTD |
PMID:18445700 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Cdon
|
cell adhesion associated, oncogene regulated
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CDON mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA panobinostat results in increased expression of CEBPB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cebpd
|
CCAAT/enhancer binding protein delta
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CEBPD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824
|
|
G
|
Celf5
|
CUGBP, Elav-like family member 5
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,876,564...8,901,069
|
|
G
|
Cep85l
|
centrosomal protein 85-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA panobinostat results in increased expression of CEP85L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:33,111,114...33,282,182
Ensembl chr20:33,115,438...33,282,238
|
|
G
|
Cfap91
|
cilia and flagella associated protein 91
|
decreases expression multiple interactions
|
ISO
|
Panobinostat results in decreased expression of CFAP91 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:75,919,129...75,962,786
Ensembl chr11:75,919,142...75,962,785
|
|
G
|
Cfap95
|
cilia and flagella associated protein 95
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:230,558,329...230,669,479
Ensembl chr 1:230,558,331...230,669,479
|
|
G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
G
|
Cgnl1
|
cingulin-like 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CGNL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:81,154,169...81,305,598
Ensembl chr 8:81,140,091...81,305,747
|
|
G
|
Chac1
|
ChaC glutathione-specific gamma-glutamylcyclotransferase 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of CHAC1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361
|
|
G
|
Chga
|
chromogranin A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA panobinostat results in increased expression of CHGA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237
|
|
G
|
Chodl
|
chondrolectin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA panobinostat results in increased expression of CHODL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:31,141,030...31,163,342
Ensembl chr11:31,141,021...31,163,334
|
|
G
|
Chrm3
|
cholinergic receptor, muscarinic 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA panobinostat results in increased expression of CHRM3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304
|
|
G
|
Chrna3
|
cholinergic receptor nicotinic alpha 3 subunit
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412
|
|
G
|
Chst15
|
carbohydrate sulfotransferase 15
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CHST15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444
|
|
G
|
Chst4
|
carbohydrate sulfotransferase 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA panobinostat results in increased expression of CHST4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648
|
|
G
|
Chsy1
|
chondroitin sulfate synthase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA panobinostat results in increased expression of CHSY1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:129,100,041...129,161,081
|
|
G
|
Cimap3
|
ciliary microtubule associated protein 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:196,163,275...196,181,604
|
|
G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA panobinostat results in increased expression of CITED2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
G
|
Cldn1
|
claudin 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of CLDN1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529
|
|
G
|
Cldn23
|
claudin 23
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CLDN23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:63,117,045...63,118,769
Ensembl chr16:63,116,781...63,118,957
|
|
G
|
Cldn4
|
claudin 4
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CLDN4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958
|
|
G
|
Cldn6
|
claudin 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA panobinostat results in increased expression of CLDN6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581
|
|
G
|
Cldn7
|
claudin 7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CLDN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905
|
|
G
|
Clgn
|
calmegin
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CLGN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325
|
|
G
|
Clic6
|
chloride intracellular channel 6
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CLIC6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344
|
|
G
|
Clp1
|
cleavage factor polyribonucleotide kinase subunit 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538
|
|
G
|
Clstn2
|
calsyntenin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA panobinostat results in increased expression of CLSTN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053
|
|
G
|
Cltrn
|
collectrin, amino acid transport regulator
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA panobinostat results in decreased expression of CLTRN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:33,993,825...34,027,124
Ensembl chr X:33,993,825...34,027,181
|
|
G
|
Clu
|
clusterin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CLU mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860
|
|
G
|
Cnksr2
|
connector enhancer of kinase suppressor of Ras 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CNKSR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:40,722,843...40,971,730
Ensembl chr X:40,722,996...40,965,604
|
|
G
|
Cnmd
|
chondromodulin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CNMD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:61,450,617...61,475,382
Ensembl chr15:61,450,450...61,475,350
|
|
G
|
Cnot4
|
CCR4-NOT transcription complex, subunit 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083
|
|
G
|
Cnrip1
|
cannabinoid receptor interacting protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA panobinostat results in increased expression of CNRIP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:95,664,435...95,707,062
Ensembl chr14:95,664,774...95,694,371
|
|
G
|
Cntn1
|
contactin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA panobinostat results in increased expression of CNTN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391
|
|
G
|
Cntn2
|
contactin 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CNTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:46,497,269...46,528,112
Ensembl chr13:46,499,396...46,528,027
|
|
G
|
Cobl
|
cordon-bleu WH2 repeat protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA panobinostat results in increased expression of COBL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:91,041,721...91,274,272
Ensembl chr14:91,041,721...91,274,257
|
|
G
|
Cobll1
|
cordon-bleu WH2 repeat protein-like 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA panobinostat results in increased expression of COBLL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460
|
|
G
|
Col11a1
|
collagen type XI alpha 1 chain
|
increases expression
|
ISO
|
panobinostat results in increased expression of COL11A1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264
|
|
G
|
Col14a1
|
collagen type XIV alpha 1 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA panobinostat results in increased expression of COL14A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA panobinostat results in increased expression of COL1A2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Col23a1
|
collagen type XXIII alpha 1 chain
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of COL23A1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:36,050,327...36,337,279
Ensembl chr10:36,050,259...36,337,897
|
|
G
|
Col5a2
|
collagen type V alpha 2 chain
|
increases expression
|
ISO
|
panobinostat results in increased expression of COL5A2 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150
|
|
G
|
Col5a3
|
collagen type V alpha 3 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA panobinostat results in increased expression of COL5A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122
|
|
G
|
Col6a1
|
collagen type VI alpha 1 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA panobinostat results in increased expression of COL6A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107
|
|
G
|
Col6a3
|
collagen type VI alpha 3 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA panobinostat results in increased expression of COL6A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990
|
|
G
|
Col9a3
|
collagen type IX alpha 3 chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA panobinostat results in increased expression of COL9A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270
|
|
G
|
Colec12
|
collectin sub-family member 12
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of COLEC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297
|
|
G
|
Colgalt2
|
collagen beta(1-O)galactosyltransferase 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of COLGALT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194
|
|
G
|
Comtd1
|
catechol-O-methyltransferase domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of COMTD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232
|
|
G
|
Coro2a
|
coronin 2A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CORO2A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602
|
|
G
|
Cpe
|
carboxypeptidase E
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CPE mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524
|
|
G
|
Cped1
|
cadherin-like and PC-esterase domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CPED1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442
|
|
G
|
Cpne4
|
copine 4
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CPNE4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:114,056,152...114,531,855
Ensembl chr 8:113,993,703...114,531,855
|
|
G
|
Cpxm2
|
carboxypeptidase X (M14 family), member 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CPXM2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:196,266,930...196,377,350
Ensembl chr 1:196,266,930...196,377,347
|
|
G
|
Cr1l
|
complement C3b/C4b receptor 1 like
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CR1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:109,138,132...109,189,068
Ensembl chr13:109,103,235...109,188,869
|
|
G
|
Cr2
|
complement C3d receptor 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:109,207,034...109,244,980
Ensembl chr13:109,213,867...109,244,552
|
|
G
|
Crabp1
|
cellular retinoic acid binding protein 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470
|
|
G
|
Crabp2
|
cellular retinoic acid binding protein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA panobinostat results in increased expression of CRABP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385
|
|
G
|
Crip1
|
cysteine rich protein 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672
|
|
G
|
Cripto
|
cripto, EGF-CFC family member
|
increases expression
|
ISO
|
Panobinostat results in increased expression of CRIPTO mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948
|
|
G
|
Crispld1
|
cysteine-rich secretory protein LCCL domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CRISPLD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:6,050,970...6,098,265
Ensembl chr 5:6,051,891...6,098,265
|
|
G
|
Cryba1
|
crystallin, beta A1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA panobinostat results in decreased expression of CRYBA1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:63,106,465...63,113,020
Ensembl chr10:63,106,475...63,112,817
|
|
G
|
Cryba4
|
crystallin, beta A4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CRYBA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:50,039,148...50,053,636
Ensembl chr12:50,047,049...50,053,634
|
|
G
|
Crybg1
|
crystallin beta-gamma domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA panobinostat results in increased expression of CRYBG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:47,425,030...47,496,918
Ensembl chr20:49,007,929...49,204,047
|
|
G
|
Csf2ra
|
colony stimulating factor 2 receptor subunit alpha
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117
|
|
G
|
Cspg5
|
chondroitin sulfate proteoglycan 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA panobinostat results in decreased expression of CSPG5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:119,098,932...119,113,191
Ensembl chr 8:119,098,925...119,143,907
|
|
G
|
Csrnp3
|
cysteine and serine rich nuclear protein 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:70,906,587...71,102,596
Ensembl chr 3:70,906,380...71,094,009
|
|
G
|
Cthrc1
|
collagen triple helix repeat containing 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654
|
|
G
|
Ctnnd2
|
catenin delta 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA panobinostat results in decreased expression of CTNND2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409
|
|
G
|
Cul3
|
cullin 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of CUL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:89,040,987...89,118,775
Ensembl chr 9:89,040,987...89,118,427
|
|
G
|
Cx3cl1
|
C-X3-C motif chemokine ligand 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA panobinostat results in increased expression of CX3CL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA panobinostat results in increased expression of CXCL12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cxcl14
|
C-X-C motif chemokine ligand 14
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA panobinostat results in increased expression of CXCL14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cxxc5
|
CXXC finger protein 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA panobinostat results in increased expression of CXXC5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA panobinostat results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of CYP1B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyren
|
cell cycle regulator of NHEJ
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of CYREN mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:64,514,477...64,518,742
|
|
G
|
Cyria
|
CYFIP related Rac1 interactor A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA Panobinostat results in increased expression of CYRIA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860
|
|
G
|
Dab1
|
DAB adaptor protein 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA panobinostat results in decreased expression of DAB1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:123,621,510...124,742,585
Ensembl chr 5:124,369,415...124,742,584
|
|
G
|
Dach2
|
dachshund family transcription factor 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DACH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:82,644,374...83,210,181
Ensembl chr X:82,644,128...83,210,000
|
|
G
|
Dact1
|
dishevelled-binding antagonist of beta-catenin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA panobinostat results in increased expression of DACT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053
|
|
G
|
Dazl
|
deleted in azoospermia-like
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA panobinostat results in decreased expression of DAZL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100
|
|
G
|
Dcaf12l2
|
DDB1 and CUL4 associated factor 12-like 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA panobinostat results in decreased expression of DCAF12L2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:123,293,761...123,296,550
Ensembl chr X:128,167,040...128,169,829
|
|
G
|
Dcaf4
|
DDB1 and CUL4 associated factor 4
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DCAF4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:108,885,932...108,912,110
|
|
G
|
Dcc
|
DCC netrin 1 receptor
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA panobinostat results in increased expression of DCC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541
|
|
G
|
Dclk1
|
doublecortin-like kinase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA panobinostat results in increased expression of DCLK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090
|
|
G
|
Dclk2
|
doublecortin-like kinase 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA panobinostat results in decreased expression of DCLK2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192
|
|
G
|
Dcun1d4
|
defective in cullin neddylation 1 domain containing 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520
|
|
G
|
Dennd1a
|
DENN domain containing 1A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA panobinostat results in decreased expression of DENND1A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:41,974,502...42,461,816
Ensembl chr 3:41,974,502...42,461,886
|
|
G
|
Dennd1b
|
DENN domain containing 1B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA panobinostat results in decreased expression of DENND1B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369
|
|
G
|
Dennd2a
|
DENN domain containing 2A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA panobinostat results in decreased expression of DENND2A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984
|
|
G
|
Dennd4a
|
DENN domain containing 4A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA panobinostat results in increased expression of DENND4A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:74,218,191...74,331,542
|
|
G
|
Depdc1b
|
DEP domain containing 1B
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of DEPDC1B mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202
|
|
G
|
Depdc7
|
DEP domain containing 7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DEPDC7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979
|
|
G
|
Deptor
|
DEP domain containing MTOR-interacting protein
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DEPTOR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041
|
|
G
|
Dhrs3
|
dehydrogenase/reductase 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DHRS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653
|
|
G
|
Diaph2
|
diaphanous-related formin 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DIAPH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:96,700,535...97,528,080
Ensembl chr X:96,700,726...97,528,080
|
|
G
|
Dipk1c
|
divergent protein kinase domain 1C
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of DIPK1C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:80,362,854...80,384,774
Ensembl chr18:80,362,982...80,386,551
|
|
G
|
Dlc1
|
DLC1 Rho GTPase activating protein
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DLC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819
|
|
G
|
Dlk1
|
delta like non-canonical Notch ligand 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of DLK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529
|
|
G
|
Dlx3
|
distal-less homeobox 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DLX3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:80,561,335...80,566,730
Ensembl chr10:80,561,335...80,566,711
|
|
G
|
Dlx6
|
distal-less homeobox 6
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of DLX6 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354
|
|
G
|
Dmrta2
|
DMRT-like family A2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA panobinostat results in increased expression of DMRTA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:130,034,473...130,040,283
Ensembl chr 5:130,034,473...130,040,222
|
|
G
|
Dmxl1
|
Dmx-like 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of DMXL1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr18:45,179,505...45,349,999
Ensembl chr18:45,179,551...45,356,406
|
|
G
|
Dner
|
delta/notch-like EGF repeat containing
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568
|
|
G
|
Dock5
|
dedicator of cytokinesis 5
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DOCK5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:46,155,124...46,334,127
Ensembl chr15:46,155,125...46,334,042
|
|
G
|
Dock9
|
dedicator of cytokinesis 9
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DOCK9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:105,018,341...105,289,799
Ensembl chr15:105,024,912...105,289,799
|
|
G
|
Dok5
|
docking protein 5
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:179,934,552...180,071,333
|
|
G
|
Dppa5
|
developmental pluripotency associated 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA panobinostat results in increased expression of DPPA5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:88,095,627...88,097,936
Ensembl chr 1:14,260,684...14,261,146
|
|
G
|
Dsc2
|
desmocollin 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DSC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466
|
|
G
|
Dst
|
dystonin
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of DST mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533
|
|
G
|
Dtwd1
|
DTW domain containing 1
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of DTWD1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 3:133,845,768...133,859,965
Ensembl chr 3:133,841,935...133,860,316
|
|
G
|
Dusp10
|
dual specificity phosphatase 10
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of DUSP10 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304
|
|
G
|
Dusp23
|
dual specificity phosphatase 23
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr13:87,630,245...87,632,400
Ensembl chr13:87,630,245...87,632,400
|
|
G
|
Dusp4
|
dual specificity phosphatase 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of DUSP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700
|
|
G
|
Dusp5
|
dual specificity phosphatase 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA panobinostat results in increased expression of DUSP5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417
|
|
G
|
Dync1i1
|
dynein cytoplasmic 1 intermediate chain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA panobinostat results in increased expression of DYNC1I1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:34,819,313...35,132,647
Ensembl chr 4:34,819,430...35,142,319
|
|
G
|
Dyrk3
|
dual specificity tyrosine phosphorylation regulated kinase 3
|
increases expression
|
ISO
|
Panobinostat results in increased expression of DYRK3 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr13:45,146,383...45,157,082
Ensembl chr13:45,146,384...45,157,249
|
|
G
|
E2f2
|
E2F transcription factor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA panobinostat results in decreased expression of E2F2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087
|
|
G
|
Eaf2
|
ELL associated factor 2
|
increases expression
|
ISO
|
Panobinostat results in increased expression of EAF2 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr11:77,465,585...77,509,993
Ensembl chr11:77,406,020...77,509,993
|
|
G
|
Ebf1
|
EBF transcription factor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA panobinostat results in increased expression of EBF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702
|
|
G
|
Ebi3
|
Epstein-Barr virus induced 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:861,441...874,731
Ensembl chr 9:870,792...874,973
|
|
G
|
Ecpas
|
Ecm29 proteasome adaptor and scaffold
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA panobinostat results in decreased expression of ECPAS mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:78,398,449...78,509,077
Ensembl chr 5:78,398,718...78,512,908
|
|
G
|
Edn1
|
endothelin 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EDN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ednra
|
endothelin receptor type A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EDNRA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284
|
|
G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA panobinostat results in increased expression of EDNRB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Efna1
|
ephrin A1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA panobinostat results in increased expression of EFNA1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726
|
|
G
|
Efna5
|
ephrin A5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA panobinostat results in decreased expression of EFNA5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348
|
|
G
|
Egf
|
epidermal growth factor
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of EGF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Egfl8
|
EGF-like-domain, multiple 8
|
increases expression
|
ISO
|
panobinostat results in increased expression of EGFL8 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr20:4,137,531...4,140,632
Ensembl chr20:4,138,053...4,141,681
|
|
G
|
Eif3m
|
eukaryotic translation initiation factor 3, subunit M
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of EIF3M mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 3:111,879,589...111,897,193
Ensembl chr 3:111,870,925...111,897,193
|
|
G
|
Eif4e3
|
eukaryotic translation initiation factor 4E family member 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of EIF4E3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:133,709,802...133,858,398
Ensembl chr 4:133,625,768...133,885,647
|
|
G
|
Elf1
|
E74 like ETS transcription factor 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ELF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:61,354,026...61,395,762
Ensembl chr15:61,330,877...61,395,758
|
|
G
|
Elf3
|
E74 like ETS transcription factor 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ELF3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380
|
|
G
|
Elf5
|
E74 like ETS transcription factor 5
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926
|
|
G
|
Elk3
|
ETS transcription factor ELK3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ELK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:29,655,693...29,691,661
|
|
G
|
Elmod1
|
ELMO domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ELMOD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322
|
|
G
|
Elovl2
|
ELOVL fatty acid elongase 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ELOVL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601
|
|
G
|
Elp4
|
elongator acetyltransferase complex subunit 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ELP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963
|
|
G
|
Emilin3
|
elastin microfibril interfacer 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of EMILIN3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:169,978,488...169,984,718
Ensembl chr 3:169,978,672...169,984,488
|
|
G
|
Emp1
|
epithelial membrane protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EMP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365
|
|
G
|
Enox1
|
ecto-NOX disulfide-thiol exchanger 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:58,924,519...59,488,919
Ensembl chr15:59,215,018...59,488,918
|
|
G
|
Enpp2
|
ectonucleotide pyrophosphatase/phosphodiesterase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA panobinostat results in increased expression of ENPP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957
|
|
G
|
Eogt
|
EGF domain specific O-linked N-acetylglucosamine transferase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA panobinostat results in increased expression of EOGT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926
|
|
G
|
Epas1
|
endothelial PAS domain protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EPAS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729
|
|
G
|
Epb41l3
|
erythrocyte membrane protein band 4.1-like 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EPB41L3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:116,502,864...116,707,274
Ensembl chr 9:116,462,807...116,707,274
|
|
G
|
Epb41l5
|
erythrocyte membrane protein band 4.1 like 5
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EPB41L5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:33,221,705...33,321,400
Ensembl chr13:33,223,589...33,321,133
|
|
G
|
Epcam
|
epithelial cell adhesion molecule
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA panobinostat results in increased expression of EPCAM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702
|
|
G
|
Epha1
|
Eph receptor A1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:72,213,022...72,227,543
Ensembl chr 4:72,213,037...72,227,474
|
|
G
|
Epha3
|
Eph receptor A3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA panobinostat results in increased expression of EPHA3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425
|
|
G
|
Epha4
|
Eph receptor A4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA panobinostat results in decreased expression of EPHA4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755
|
|
G
|
Epha7
|
Eph receptor A7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of EPHA7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058
|
|
G
|
Ephb2
|
Eph receptor B2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of EPHB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:154,179,065...154,360,459
Ensembl chr 5:154,179,065...154,360,615
|
|
G
|
Epn3
|
epsin 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:79,935,857...79,946,121
Ensembl chr10:79,935,857...79,944,235
|
|
G
|
Eps8l2
|
EPS8 signaling adaptor L2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:205,875,825...205,901,109
Ensembl chr 1:205,875,801...205,901,101
|
|
G
|
Epsti1
|
epithelial stromal interaction 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA panobinostat results in increased expression of EPSTI1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:59,692,712...59,791,376
Ensembl chr15:59,693,142...59,791,380
|
|
G
|
Erap1
|
endoplasmic reticulum aminopeptidase 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA panobinostat results in decreased expression of ERAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056
|
|
G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA panobinostat results in increased expression of ERBB3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120
|
|
G
|
Erp27
|
endoplasmic reticulum protein 27
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA panobinostat results in increased expression of ERP27 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072
|
|
G
|
Esrp1
|
epithelial splicing regulatory protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ESRP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:29,224,831...29,279,381
Ensembl chr 5:29,225,360...29,279,278
|
|
G
|
Esrp2
|
epithelial splicing regulatory protein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA panobinostat results in increased expression of ESRP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:50,944,401...50,951,919
Ensembl chr19:50,944,401...50,951,568
|
|
G
|
Etnk1
|
ethanolamine kinase 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ETNK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:177,856,960...177,924,721
|
|
G
|
Ets1
|
ETS proto-oncogene 1, transcription factor
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ETS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021
|
|
G
|
Etv1
|
ETS variant transcription factor 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA panobinostat results in decreased expression of ETV1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959
|
|
G
|
Ext1
|
exostosin glycosyltransferase 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA panobinostat results in decreased expression of EXT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:86,259,900...86,544,567
|
|
G
|
Ezr
|
ezrin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA panobinostat results in increased expression of EZR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573
|
|
G
|
F2rl1
|
F2R like trypsin receptor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA panobinostat results in increased expression of F2RL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954
|
|
G
|
F2rl2
|
coagulation factor II (thrombin) receptor-like 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA panobinostat results in decreased expression of F2RL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473
|
|
G
|
Fabp3
|
fatty acid binding protein 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA panobinostat results in increased expression of FABP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881
|
|
G
|
Fam110b
|
family with sequence similarity 110, member B
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:23,586,867...23,799,583
|
|
G
|
Fam124a
|
family with sequence similarity 124 member A
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FAM124A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:40,975,789...41,031,069
Ensembl chr15:40,975,877...41,029,628
|
|
G
|
Fam13c
|
family with sequence similarity 13, member C
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA panobinostat results in increased expression of FAM13C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:18,064,706...18,186,888
Ensembl chr20:18,064,706...18,286,674
|
|
G
|
Fam149a
|
family with sequence similarity 149, member A
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FAM149A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:53,587,841...53,647,072
Ensembl chr16:53,587,841...53,647,072
|
|
G
|
Fam163a
|
family with sequence similarity 163, member A
|
affects expression multiple interactions
|
ISO
|
panobinostat affects the expression of FAM163A mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:70,813,134...70,891,316
|
|
G
|
Fam168a
|
family with sequence similarity 168, member A
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FAM168A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:164,469,447...164,615,542
Ensembl chr 1:164,469,471...164,615,506
|
|
G
|
Fam241a
|
family with sequence similarity 241 member A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770
|
|
G
|
Fam43a
|
family with sequence similarity 43, member A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FAM43A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297
|
|
G
|
Fam89a
|
family with sequence similarity 89, member A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FAM89A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:69,607,391...69,620,019
Ensembl chr19:69,607,391...69,620,019
|
|
G
|
Fank1
|
fibronectin type III and ankyrin repeat domains 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA panobinostat results in decreased expression of FANK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:188,577,512...188,685,501
Ensembl chr 1:198,007,547...198,115,561
|
|
G
|
Fat3
|
FAT atypical cadherin 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FAT3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:20,972,840...21,555,679
Ensembl chr 8:20,972,840...21,555,240
|
|
G
|
Faxc
|
failed axon connections homolog, metaxin like GST domain containing
|
affects expression multiple interactions
|
ISO
|
panobinostat affects the expression of FAXC mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 5:40,277,167...40,336,503
Ensembl chr 5:40,277,135...40,344,076
|
|
G
|
Fbln7
|
fibulin 7
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FBLN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:136,564,825...136,601,205
Ensembl chr 3:136,564,917...136,601,198
|
|
G
|
Fbn1
|
fibrillin 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA panobinostat results in decreased expression of FBN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283
|
|
G
|
Fbxl13
|
F-box and leucine-rich repeat protein 13
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:14,307,032...14,505,491
Ensembl chr 4:14,307,096...14,499,585
|
|
G
|
Fbxo2
|
F-box protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FBXO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508
|
|
G
|
Fbxo8
|
F-box protein 8
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr16:33,665,305...33,711,215
Ensembl chr16:38,676,014...38,721,906
|
|
G
|
Fbxo9
|
f-box protein 9
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:87,838,787...87,864,362
Ensembl chr 8:87,838,789...87,864,504
|
|
G
|
Fermt1
|
FERM domain containing kindlin 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FERMT1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419
|
|
G
|
Fez1
|
fasciculation and elongation protein zeta 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA panobinostat results in decreased expression of FEZ1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:44,733,300...44,784,097
|
|
G
|
Fezf2
|
Fez family zinc finger 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA panobinostat results in decreased expression of FEZF2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:15,199,045...15,207,982
Ensembl chr15:15,204,193...15,207,982
|
|
G
|
Fgd5
|
FYVE, RhoGEF and PH domain containing 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA panobinostat results in increased expression of FGD5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:126,054,201...126,151,698
Ensembl chr 4:126,054,210...126,151,697
|
|
G
|
Fgf18
|
fibroblast growth factor 18
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933
|
|
G
|
Fgf19
|
fibroblast growth factor 19
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FGF19 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267
|
|
G
|
Fgf8
|
fibroblast growth factor 8
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FGF8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605
|
|
G
|
Fgf9
|
fibroblast growth factor 9
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of FGF9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926
|
|
G
|
Fgfbp3
|
fibroblast growth factor binding protein 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FGFBP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:244,056,307...244,065,654
|
|
G
|
Fgfr3
|
fibroblast growth factor receptor 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA panobinostat results in increased expression of FGFR3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209
|
|
G
|
Fhod3
|
formin homology 2 domain containing 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA panobinostat results in decreased expression of FHOD3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:16,267,830...16,700,508
Ensembl chr18:16,267,977...16,700,508
|
|
G
|
Fign
|
fidgetin, microtubule severing factor
|
affects expression multiple interactions
|
ISO
|
panobinostat affects the expression of FIGN mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 3:69,045,918...69,169,148
Ensembl chr 3:69,045,050...69,169,988
|
|
G
|
Fjx1
|
four-jointed box kinase 1
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of FJX1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479
|
|
G
|
Flnb
|
filamin B
|
increases expression
|
ISO
|
panobinostat results in increased expression of FLNB mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr15:19,392,212...19,525,278
Ensembl chr15:19,392,216...19,525,209
|
|
G
|
Flrt2
|
fibronectin leucine rich transmembrane protein 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA panobinostat results in decreased expression of FLRT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004
|
|
G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA panobinostat results in increased expression of FLT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750
|
|
G
|
Fndc5
|
fibronectin type III domain containing 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA panobinostat results in decreased expression of FNDC5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:146,765,951...146,775,611
Ensembl chr 5:146,751,416...146,778,540
|
|
G
|
Foxc1
|
forkhead box C1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FOXC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:32,840,119...32,844,100
Ensembl chr17:32,805,858...32,844,347
|
|
G
|
Foxc2
|
forkhead box C2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FOXC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977
|
|
G
|
Foxd3
|
forkhead box D3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FOXD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786
|
|
G
|
Foxh1
|
forkhead box H1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FOXH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:110,268,608...110,272,105
Ensembl chr 7:110,268,612...110,270,692
|
|
G
|
Foxo1
|
forkhead box O1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of FOXO1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Fras1
|
Fraser extracellular matrix complex subunit 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664
|
|
G
|
Frem1
|
Fras1 related extracellular matrix 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA panobinostat results in increased expression of FREM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:102,367,201...102,515,464
Ensembl chr 5:102,367,201...102,515,404
|
|
G
|
Frrs1l
|
ferric-chelate reductase 1-like
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA panobinostat results in decreased expression of FRRS1L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:76,451,101...76,485,319
Ensembl chr 5:76,451,101...76,485,316
|
|
G
|
Frzb
|
frizzled-related protein
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA panobinostat results in decreased expression of FRZB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096
|
|
G
|
Fut4
|
fucosyltransferase 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA panobinostat results in increased expression of FUT4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436
|
|
G
|
Fut9
|
fucosyltransferase 9
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA panobinostat results in decreased expression of FUT9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:44,148,371...44,361,209
Ensembl chr 5:44,146,152...44,362,823
|
|
G
|
Fzd10
|
frizzled class receptor 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA panobinostat results in increased expression of FZD10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646
|
|
G
|
Fzd2
|
frizzled class receptor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA panobinostat results in decreased expression of FZD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:88,061,988...88,063,898
Ensembl chr10:88,061,667...88,065,396
|
|
G
|
Fzd3
|
frizzled class receptor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA panobinostat results in decreased expression of FZD3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960
|
|
G
|
Fzd5
|
frizzled class receptor 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA panobinostat results in decreased expression of FZD5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612
|
|
G
|
Fzd7
|
frizzled class receptor 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA panobinostat results in increased expression of FZD7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585
|
|
G
|
Fzd8
|
frizzled class receptor 8
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961
|
|
G
|
Gabrb2
|
gamma-aminobutyric acid type A receptor subunit beta 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA panobinostat results in increased expression of GABRB2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171
|
|
G
|
Gabrb3
|
gamma-aminobutyric acid type A receptor subunit beta 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA panobinostat results in increased expression of GABRB3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:117,431,842...117,836,725
|
|
G
|
Gabrp
|
gamma-aminobutyric acid type A receptor subunit pi
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:18,647,243...18,673,806
Ensembl chr10:18,647,243...18,673,727
|
|
G
|
Gad1
|
glutamate decarboxylase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA panobinostat results in increased expression of GAD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759
|
|
G
|
Gad2
|
glutamate decarboxylase 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr17:89,671,718...89,734,246
Ensembl chr17:89,671,716...89,941,089
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA] panobinostat results in increased expression of GADD45A mRNA
|
CTD |
PMID:23681230 PMID:26272509 PMID:27188386 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gadd45b
|
growth arrest and DNA-damage-inducible, beta
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GADD45B mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718
|
|
G
|
Gadd45g
|
growth arrest and DNA-damage-inducible, gamma
|
multiple interactions increases expression
|
ISO
|
GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]
|
CTD |
PMID:23681230 |
|
NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369
|
|
G
|
Galnt18
|
polypeptide N-acetylgalactosaminyltransferase 18
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA panobinostat results in increased expression of GALNT18 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:175,027,832...175,338,883
Ensembl chr 1:175,027,839...175,338,883
|
|
G
|
Galnt3
|
polypeptide N-acetylgalactosaminyltransferase 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA panobinostat results in increased expression of GALNT3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323
|
|
G
|
Gap43
|
growth associated protein 43
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA panobinostat results in increased expression of GAP43 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797
|
|
G
|
Garin1b
|
golgi associated RAB2 interactor 1B
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of GARIN1B mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 4:58,880,537...58,903,966
Ensembl chr 4:58,880,594...58,903,961
|
|
G
|
Gas7
|
growth arrest specific 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA panobinostat results in increased expression of GAS7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:52,651,690...52,882,244
Ensembl chr10:52,651,690...52,882,244
|
|
G
|
Gata2
|
GATA binding protein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA panobinostat results in increased expression of GATA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055
|
|
G
|
Gata3
|
GATA binding protein 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA panobinostat results in increased expression of GATA3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670
|
|
G
|
Gata4
|
GATA binding protein 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA panobinostat results in decreased expression of GATA4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609
|
|
G
|
Gata6
|
GATA binding protein 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,458,253...2,492,322
|
|
G
|
Gbx2
|
gastrulation brain homeobox 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GBX2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:97,957,304...97,959,883
Ensembl chr 9:97,957,304...97,959,883
|
|
G
|
Gchfr
|
GTP cyclohydrolase I feedback regulator
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GCHFR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926
|
|
G
|
Gdf10
|
growth differentiation factor 10
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794
|
|
G
|
Gja3
|
gap junction protein, alpha 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GJA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:35,296,946...35,322,405
Ensembl chr15:35,295,523...35,322,809
|
|
G
|
Gjb2
|
gap junction protein, beta 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877
|
|
G
|
Gje1
|
gap junction protein, epsilon 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:10,905,890...10,911,800
Ensembl chr 1:10,905,890...10,908,305
|
|
G
|
Gkap1
|
G kinase anchoring protein 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA panobinostat results in decreased expression of GKAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:6,389,377...6,429,091
Ensembl chr17:6,389,377...6,438,279
|
|
G
|
Glb1l
|
galactosidase, beta 1-like
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 9:84,141,993...84,154,176
Ensembl chr 9:84,143,841...84,154,176
|
|
G
|
Glcci1
|
glucocorticoid induced 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GLCCI1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:36,307,956...36,635,614
Ensembl chr 4:37,529,364...37,599,802 Ensembl chr 4:37,529,364...37,599,802
|
|
G
|
Glis3
|
GLIS family zinc finger 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GLIS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221
|
|
G
|
Glrx2
|
glutaredoxin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA panobinostat results in increased expression of GLRX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:58,032,199...58,055,061
Ensembl chr13:58,032,401...58,043,150
|
|
G
|
Gls
|
glutaminase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA panobinostat results in increased expression of GLS mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861
|
|
G
|
Gnas
|
GNAS complex locus
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA panobinostat results in increased expression of GNAS mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536
|
|
G
|
Gng11
|
G protein subunit gamma 11
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA panobinostat results in increased expression of GNG11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,977,681...32,983,121
Ensembl chr 4:32,977,664...32,984,438
|
|
G
|
Gng8
|
G protein subunit gamma 8
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA panobinostat results in decreased expression of GNG8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:86,692,609...86,696,463
Ensembl chr 1:86,692,642...86,696,408
|
|
G
|
Gnl3l
|
G protein nucleolar 3 like
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr X:23,404,324...23,437,501
Ensembl chr X:23,404,324...23,439,315
|
|
G
|
Gpc3
|
glypican 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GPC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:136,789,770...137,157,598
Ensembl chr X:136,789,770...137,157,639
|
|
G
|
Gpc4
|
glypican 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GPC4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:136,565,536...136,676,142
Ensembl chr X:136,565,591...136,676,057
|
|
G
|
Gpc6
|
glypican 6
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA panobinostat results in decreased expression of GPC6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:100,437,415...101,435,038
Ensembl chr15:100,437,943...101,435,027
|
|
G
|
Gpd1l
|
glycerol-3-phosphate dehydrogenase 1 like
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GPD1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:123,466,667...123,498,908
|
|
G
|
Gpr173
|
G-protein coupled receptor 173
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GPR173 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:24,925,634...24,950,485
Ensembl chr X:24,922,704...24,950,887
|
|
G
|
Gpr183
|
G protein-coupled receptor 183
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of GPR183 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977
|
|
G
|
Gpr27
|
G protein-coupled receptor 27
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GPR27 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:133,884,894...133,886,027
Ensembl chr 4:133,883,234...133,904,093
|
|
G
|
Gpr37
|
G protein-coupled receptor 37
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GPR37 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494
|
|
G
|
Grem1
|
gremlin 1, DAN family BMP antagonist
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GREM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089
|
|
G
|
Grhl1
|
grainyhead-like transcription factor 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 6:46,935,947...46,986,126
Ensembl chr 6:46,935,967...46,980,264
|
|
G
|
Grhl2
|
grainyhead-like transcription factor 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:70,280,360...70,415,277
Ensembl chr 7:70,285,310...70,415,274
|
|
G
|
Grhl3
|
grainyhead-like transcription factor 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GRHL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:153,057,760...153,089,890
|
|
G
|
Gria1
|
glutamate ionotropic receptor AMPA type subunit 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309
|
|
G
|
Gria3
|
glutamate ionotropic receptor AMPA type subunit 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GRIA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679
|
|
G
|
Grik3
|
glutamate ionotropic receptor kainate type subunit 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of GRIK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873
|
|
G
|
Grin2a
|
glutamate ionotropic receptor NMDA type subunit 2A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378
|
|
G
|
Grm3
|
glutamate metabotropic receptor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA panobinostat results in decreased expression of GRM3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Gsta2
|
glutathione S-transferase alpha 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
G
|
Gypc
|
glycophorin C
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of GYPC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,434,922...24,440,053
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases expression
|
ISO
|
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]
|
CTD |
PMID:22923501 PMID:23681230 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
H2bc12
|
H2B clustered histone 12
|
decreases expression multiple interactions
|
ISO
|
Panobinostat results in decreased expression of H2BC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816
|
|
G
|
H3f4
|
H3.4 histone, cluster member
|
increases acetylation
|
ISO
|
Panobinostat results in increased acetylation of H3-4 protein
|
CTD |
PMID:19215824 |
|
NCBI chr10:44,240,282...44,240,842
|
|
G
|
Hacd1
|
3-hydroxyacyl-CoA dehydratase 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HACD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:81,992,284...82,014,676
Ensembl chr17:81,992,292...82,014,592
|
|
G
|
Hand1
|
heart and neural crest derivatives expressed 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:42,507,117...42,509,684
Ensembl chr10:42,507,122...42,509,684
|
|
G
|
Hapln1
|
hyaluronan and proteoglycan link protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA panobinostat results in increased expression of HAPLN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098
|
|
G
|
Has2
|
hyaluronan synthase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA panobinostat results in increased expression of HAS2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535
|
|
G
|
Hck
|
HCK proto-oncogene, Src family tyrosine kinase
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935
|
|
G
|
Hdac8
|
histone deacetylase 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA panobinostat results in increased expression of HDAC8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:71,425,240...71,632,865
Ensembl chr X:71,394,928...71,632,865
|
|
G
|
Hdac9
|
histone deacetylase 9
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of HDAC9 mRNA
|
CTD |
PMID:30481203 |
|
NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835
|
|
G
|
Heg1
|
heart development protein with EGF-like domains 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA panobinostat results in decreased expression of HEG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:80,512,096...80,600,150
Ensembl chr11:80,512,096...80,600,092
|
|
G
|
Hes2
|
hes family bHLH transcription factor 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HES2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:167,947,948...167,964,660
Ensembl chr 5:167,949,918...167,955,601
|
|
G
|
Hes5
|
hes family bHLH transcription factor 5
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of HES5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021
|
|
G
|
Hesx1
|
HESX homeobox 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of HESX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,198,589...2,200,694
Ensembl chr16:2,198,589...2,200,694
|
|
G
|
Hey2
|
hes-related family bHLH transcription factor with YRPW motif 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA panobinostat results in increased expression of HEY2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:28,641,057...28,651,187
|
|
G
|
Hhip
|
Hedgehog-interacting protein
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr19:44,768,038...44,856,878
Ensembl chr19:44,767,536...44,862,795
|
|
G
|
Hip1
|
huntingtin interacting protein 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of HIP1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr12:26,769,868...26,904,367
Ensembl chr12:26,769,961...26,904,296
|
|
G
|
Hk1
|
hexokinase 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814
|
|
G
|
Hmces
|
5-hydroxymethylcytosine binding, ES cell specific
|
increases expression
|
ISO
|
Panobinostat results in increased expression of HMCES mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 4:121,950,129...121,972,937
Ensembl chr 4:121,950,840...121,972,891
|
|
G
|
Hmgcll1
|
3-hydroxy-3-methylglutaryl-CoA lyase like 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of HMGCLL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,757,301...76,887,300
Ensembl chr 8:85,637,958...85,767,740
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA panobinostat results in increased expression of HMOX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hmx2
|
H6 family homeobox 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:195,749,284...195,758,347
Ensembl chr 1:195,749,284...195,756,945
|
|
G
|
Hnmt
|
histamine N-methyltransferase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HNMT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:26,978,274...27,010,291
Ensembl chr 3:26,977,933...27,010,482
|
|
G
|
Hnrnpr
|
heterogeneous nuclear ribonucleoprotein R
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:153,826,482...153,872,272
Ensembl chr 5:153,826,692...153,858,344
|
|
G
|
Homez
|
homeobox and leucine zipper encoding
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:32,292,897...32,309,564
Ensembl chr15:32,291,048...32,321,319
|
|
G
|
Hoxa1
|
homeobox A1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209
|
|
G
|
Hpdl
|
4-hydroxyphenylpyruvate dioxygenase-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA panobinostat results in increased expression of HPDL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:135,523,258...135,524,864
Ensembl chr 5:135,523,262...135,535,704
|
|
G
|
Hpgd
|
15-hydroxyprostaglandin dehydrogenase
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831
|
|
G
|
Hps1
|
HPS1, biogenesis of lysosomal organelles complex 3 subunit 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA panobinostat results in increased expression of HPS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:251,500,427...251,526,529
Ensembl chr 1:251,500,427...251,526,739
|
|
G
|
Hrk
|
harakiri, BCL2 interacting protein
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HRK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561
|
|
G
|
Hs3st3b1
|
heparan sulfate-glucosamine 3-sulfotransferase 3B1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of HS3ST3B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185
|
|
G
|
Hspa4l
|
heat shock protein family A (Hsp70) member 4 like
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of HSPA4L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ICAM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Id4
|
inhibitor of DNA binding 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA panobinostat results in increased expression of ID4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,595,724...16,598,492
|
|
G
|
Idh3a
|
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA panobinostat results in increased expression of IDH3A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223
|
|
G
|
Ier3
|
immediate early response 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of IER3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ifi30
|
IFI30, lysosomal thiol reductase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA panobinostat results in increased expression of IFI30 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:18,709,570...18,713,635
Ensembl chr16:18,709,563...18,715,711
|
|
G
|
Ifitm1
|
interferon induced transmembrane protein 1
|
increases expression multiple interactions
|
ISO
|
Panobinostat results in increased expression of IFITM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776
|
|
G
|
Ifnar2
|
interferon alpha and beta receptor subunit 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr11:44,099,574...44,131,941
Ensembl chr11:44,099,753...44,131,937
|
|
G
|
Ift25
|
intraflagellar transport 25
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA Panobinostat results in decreased expression of IFT25 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:127,264,450...127,291,225
Ensembl chr 5:127,264,498...127,291,225
|
|
G
|
Igdcc3
|
immunoglobulin superfamily, DCC subclass, member 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of IGDCC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:74,556,348...74,603,136
Ensembl chr 8:74,556,348...74,603,136
|
|
G
|
Igf2
|
insulin-like growth factor 2
|
increases expression
|
ISO
|
panobinostat results in increased expression of IGF2 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667
|
|
G
|
Igfbp3
|
insulin-like growth factor binding protein 3
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of IGFBP3 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944
|
|
G
|
Igfbp7
|
insulin-like growth factor binding protein 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA panobinostat results in increased expression of IGFBP7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620
|
|
G
|
Igsf21
|
immunoglobin superfamily, member 21
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:157,570,964...157,795,290
Ensembl chr 5:157,570,964...157,795,290
|
|
G
|
Il17rd
|
interleukin 17 receptor D
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of IL17RD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,235,172...2,489,827
Ensembl chr16:2,235,169...2,301,850
|
|
G
|
Il1rapl1
|
interleukin 1 receptor accessory protein-like 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of IL1RAPL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:55,322,779...56,827,486
Ensembl chr X:55,328,964...56,826,613
|
|
G
|
Il20rb
|
interleukin 20 receptor subunit beta
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of IL20RB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:109,854,012...109,889,363
|
|
G
|
Il27ra
|
interleukin 27 receptor subunit alpha
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of IL27RA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760
|
|
G
|
Il3ra
|
interleukin 3 receptor subunit alpha
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA Panobinostat results in increased expression of IL3RA mRNA
|
CTD |
PMID:21791302 PMID:33770205 |
|
NCBI chr12:21,431,848...21,437,336
Ensembl chr12:21,431,848...21,437,250
|
|
G
|
Inf2
|
inverted formin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA panobinostat results in increased expression of INF2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:137,470,259...137,497,039
Ensembl chr 6:137,470,286...137,497,039
|
|
G
|
Inhbe
|
inhibin subunit beta E
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA panobinostat results in increased expression of INHBE mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519
|
|
G
|
Inpp4b
|
inositol polyphosphate-4-phosphatase type II B
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr19:42,824,710...43,575,039
Ensembl chr19:42,829,871...43,185,091
|
|
G
|
Inpp5d
|
inositol polyphosphate-5-phosphatase D
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589
|
|
G
|
Inpp5f
|
inositol polyphosphate-5-phosphatase F
|
increases expression
|
ISO
|
Panobinostat results in increased expression of INPP5F mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 1:192,620,891...192,700,681
Ensembl chr 1:192,620,891...192,700,681
|
|
G
|
Insc
|
INSC, spindle orientation adaptor protein
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of INSC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:178,427,360...178,534,827
Ensembl chr 1:178,427,423...178,535,047
|
|
G
|
Iqca1
|
IQ motif containing with AAA domain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA Panobinostat results in increased expression of DRC11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:98,073,887...98,190,066
|
|
G
|
Iqgap1
|
IQ motif containing GTPase activating protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA panobinostat results in increased expression of IQGAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043
|
|
G
|
Irf6
|
interferon regulatory factor 6
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of IRF6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:107,200,876...107,220,083
Ensembl chr13:107,200,731...107,220,049
|
|
G
|
Irx1
|
iroquois homeobox 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA panobinostat results in increased expression of IRX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:33,123,122...33,128,951
Ensembl chr 1:33,123,122...33,128,951
|
|
G
|
Irx2
|
iroquois homeobox 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA panobinostat results in increased expression of IRX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:32,489,512...32,494,930
Ensembl chr 1:32,489,512...32,494,930
|
|
G
|
Irx3
|
iroquois homeobox 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA panobinostat results in increased expression of IRX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:31,384,803...31,388,241
Ensembl chr19:31,384,833...31,388,238
|
|
G
|
Isl1
|
ISL LIM homeobox 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:49,813,618...49,823,442
Ensembl chr 2:49,813,618...49,823,442
|
|
G
|
Itga8
|
integrin subunit alpha 8
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ITGA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633
|
|
G
|
Itga9
|
integrin subunit alpha 9
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ITGA9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:127,185,244...127,493,296
Ensembl chr 8:127,169,226...127,493,296
|
|
G
|
Itgb5
|
integrin subunit beta 5
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ITGB5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:80,333,588...80,449,373
Ensembl chr11:80,333,590...80,449,373
|
|
G
|
Itih5
|
inter-alpha-trypsin inhibitor heavy chain 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA Panobinostat results in increased expression of ITIH5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496
|
|
G
|
Itm2a
|
integral membrane protein 2A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:76,559,183...76,565,144
Ensembl chr X:76,559,181...76,565,437
|
|
G
|
Itpr2
|
inositol 1,4,5-trisphosphate receptor, type 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA panobinostat results in increased expression of ITPR2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763
|
|
G
|
Jade2
|
jade family PHD finger 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of JADE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532
|
|
G
|
Jarid2
|
jumonji and AT-rich interaction domain containing 2
|
increases expression
|
ISO
|
Panobinostat results in increased expression of JARID2 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970
|
|
G
|
Jazf1
|
JAZF zinc finger 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of JAZF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:83,210,054...83,513,790
Ensembl chr 4:83,210,058...83,513,644
|
|
G
|
Jcad
|
junctional cadherin 5 associated
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of JCAD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:57,784,634...57,826,213
Ensembl chr17:57,784,634...57,826,183
|
|
G
|
Jdp2
|
Jun dimerization protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of JDP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
panobinostat results in increased expression of JUN mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Kank4
|
KN motif and ankyrin repeat domains 4
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KANK4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:118,517,971...118,581,002
|
|
G
|
Kat2b
|
lysine acetyltransferase 2B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA panobinostat results in decreased expression of KAT2B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616
|
|
G
|
Kat6a
|
lysine acetyltransferase 6A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:75,787,411...75,868,584
Ensembl chr16:75,787,411...75,866,099
|
|
G
|
Kat7
|
lysine acetyltransferase 7
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA panobinostat results in decreased expression of KAT7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:80,718,335...80,752,387
Ensembl chr10:80,718,335...80,752,387
|
|
G
|
Kbtbd11
|
kelch repeat and BTB domain containing 11
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of KBTBD11 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390
|
|
G
|
Kcna7
|
potassium voltage-gated channel subfamily A member 7
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:105,022,549...105,028,041
Ensembl chr 1:105,022,549...105,028,041
|
|
G
|
Kcnc1
|
potassium voltage-gated channel subfamily C member 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA panobinostat results in decreased expression of KCNC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:106,039,247...106,081,034
Ensembl chr 1:106,039,237...106,081,033
|
|
G
|
Kcnd2
|
potassium voltage-gated channel subfamily D member 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA panobinostat results in decreased expression of KCND2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522
|
|
G
|
Kcng1
|
potassium voltage-gated channel modifier subfamily G member 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KCNG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:177,379,593...177,412,986
Ensembl chr 3:177,392,031...177,411,507
|
|
G
|
Kcnh5
|
potassium voltage-gated channel subfamily H member 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA panobinostat results in decreased expression of KCNH5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:99,350,947...99,643,856
Ensembl chr 6:99,360,302...99,643,856
|
|
G
|
Kcnj13
|
potassium inwardly-rectifying channel, subfamily J, member 13
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA panobinostat results in decreased expression of KCNJ13 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:95,509,228...95,528,400
Ensembl chr 9:95,510,877...95,520,817
|
|
G
|
Kcnj3
|
potassium inwardly-rectifying channel, subfamily J, member 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:60,353,990...60,518,110
Ensembl chr 3:60,354,146...60,518,104
|
|
G
|
Kcnk1
|
potassium two pore domain channel subfamily K member 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr19:70,856,985...70,895,053
Ensembl chr19:70,856,985...70,895,051
|
|
G
|
Kcnk10
|
potassium two pore domain channel subfamily K member 10
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA panobinostat results in decreased expression of KCNK10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:123,419,778...123,555,820
Ensembl chr 6:123,423,950...123,555,614
|
|
G
|
Kcnmb4
|
potassium calcium-activated channel subfamily M regulatory beta subunit 4
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281
|
|
G
|
Kcnn3
|
potassium calcium-activated channel subfamily N member 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA panobinostat results in decreased expression of KCNN3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:177,227,276...177,378,849
Ensembl chr 2:177,234,327...177,379,693
|
|
G
|
Kcnv1
|
potassium voltage-gated channel modifier subfamily V member 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:78,145,319...78,153,794
Ensembl chr 7:78,145,319...78,153,816
|
|
G
|
Kctd1
|
potassium channel tetramerization domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA panobinostat results in increased expression of KCTD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:6,396,947...6,591,026
Ensembl chr18:6,396,947...6,515,191
|
|
G
|
Kctd12
|
potassium channel tetramerization domain containing 12
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA panobinostat results in increased expression of KCTD12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539
|
|
G
|
Kdr
|
kinase insert domain receptor
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
G
|
Kiaa0040
|
KIAA0040 ortholog
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA panobinostat results in increased expression of KIAA0040 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:74,807,959...74,845,530
Ensembl chr13:74,807,982...74,845,530
|
|
G
|
Kiaa1549
|
KIAA1549 homolog
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of KIAA1549 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:67,807,635...67,935,303
Ensembl chr 4:67,811,803...67,935,360
|
|
G
|
Kiaa1755
|
KIAA1755 ortholog
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KIAA1755 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:167,270,476...167,305,337
Ensembl chr 3:167,192,612...167,304,240
|
|
G
|
Kif13a
|
kinesin family member 13A
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of KIF13A mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760
|
|
G
|
Kif28
|
kinesin family member 28
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr13:93,959,492...94,014,255
Ensembl chr13:93,959,492...94,014,255
|
|
G
|
Kif5c
|
kinesin family member 5C
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:54,441,310...54,594,813
|
|
G
|
Kifap3
|
kinesin-associated protein 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KIFAP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:78,660,849...78,797,821
Ensembl chr13:78,660,871...78,797,820
|
|
G
|
Kiss1r
|
KISS1 receptor
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424
|
|
G
|
Kit
|
KIT proto-oncogene receptor tyrosine kinase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KIT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812
|
|
G
|
Kitlg
|
KIT ligand
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KITLG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793
|
|
G
|
Kiz
|
kizuna centrosomal protein
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of KIZ mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:154,730,873...154,838,410
Ensembl chr 3:154,730,634...154,838,410
|
|
G
|
Klf15
|
KLF transcription factor 15
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KLF15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373
|
|
G
|
Klf4
|
KLF transcription factor 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592
|
|
G
|
Klf5
|
KLF transcription factor 5
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KLF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262
|
|
G
|
Klf6
|
KLF transcription factor 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA panobinostat results in increased expression of KLF6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601
|
|
G
|
Klhl14
|
kelch-like family member 14
|
increases expression
|
ISO
|
panobinostat results in increased expression of KLHL14 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr18:13,079,159...13,192,728
Ensembl chr18:13,079,159...13,193,557
|
|
G
|
Klk10
|
kallikrein related-peptidase 10
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:103,371,638...103,375,918
Ensembl chr 1:103,371,638...103,375,918
|
|
G
|
Klk8
|
kallikrein related-peptidase 8
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA panobinostat results in increased expression of KLK8 mRNA
|
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 1:103,388,352...103,395,195
Ensembl chr 1:103,388,352...103,395,195
|
|
G
|
Klrg2
|
killer cell lectin like receptor G2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KLRG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:68,314,347...68,341,759
Ensembl chr 4:68,330,660...68,341,043
|
|
G
|
Kremen1
|
kringle containing transmembrane protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of KREMEN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614
|
|
G
|
Krt18
|
keratin 18
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA panobinostat results in increased expression of KRT18 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848 Ensembl chr10:135,035,982...135,039,848
|
|
G
|
Krt19
|
keratin 19
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952
|
|
G
|
Krt8
|
keratin 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA panobinostat results in increased expression of KRT8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
G
|
L1cam
|
L1 cell adhesion molecule
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA panobinostat results in increased expression of L1CAM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077
|
|
G
|
L1td1
|
LINE-1 type transposase domain containing 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of L1TD1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 5:118,488,688...118,501,591
Ensembl chr 5:118,488,688...118,501,591
|
|
G
|
Lacc1
|
laccase domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LACC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:58,799,477...58,816,840
Ensembl chr15:58,786,637...58,816,840
|
|
G
|
Lactb
|
lactamase, beta
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LACTB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716
|
|
G
|
Lama2
|
laminin subunit alpha 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LAMA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056
|
|
G
|
Lama4
|
laminin subunit alpha 4
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LAMA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:43,946,898...44,087,972
Ensembl chr20:43,946,898...44,087,972
|
|
G
|
Lamc2
|
laminin subunit gamma 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LAMC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
G
|
Lamp2
|
lysosomal-associated membrane protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LAMP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:122,038,734...122,087,745
Ensembl chr X:121,922,187...122,087,675
|
|
G
|
Layn
|
layilin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LAYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:60,261,325...60,280,797
Ensembl chr 8:60,263,456...60,281,418
|
|
G
|
Lctl
|
lactase-like
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LCTL mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:73,506,096...73,534,668
Ensembl chr 8:73,513,634...73,534,668
|
|
G
|
Ldhd
|
lactate dehydrogenase D
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LDHD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:56,492,827...56,497,695
Ensembl chr19:56,482,924...56,509,197
|
|
G
|
Lemd1
|
LEM domain containing 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562
|
|
G
|
Lgals1
|
galectin 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800
|
|
G
|
Lgals3
|
galectin 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LGALS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737
|
|
G
|
Lhfpl6
|
LHFPL tetraspan subfamily member 6
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LHFPL6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737
|
|
G
|
Lhx2
|
LIM homeobox 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA panobinostat results in decreased expression of LHX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645
|
|
G
|
Lhx8
|
LIM homeobox 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA panobinostat results in increased expression of LHX8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376
|
|
G
|
Lifr
|
LIF receptor subunit alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA panobinostat results in increased expression of LIFR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:57,952,975...58,020,364
|
|
G
|
Lim2
|
lens intrinsic membrane protein 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:102,974,188...102,980,358
Ensembl chr 1:102,974,188...102,980,358
|
|
G
|
Limch1
|
LIM and calponin homology domains 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LIMCH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,466,433...41,778,837
|
|
G
|
Lin28b
|
lin-28 homolog B
|
multiple interactions affects expression decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein] panobinostat affects the expression of LIN28B mRNA panobinostat results in decreased expression of LIN28B protein
|
CTD |
PMID:26733615 |
|
NCBI chr20:50,447,700...50,547,135
Ensembl chr20:50,450,971...50,541,968
|
|
G
|
Lingo2
|
leucine rich repeat and Ig domain containing 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LINGO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:50,370,744...51,687,252
Ensembl chr 5:55,156,997...56,489,155
|
|
G
|
Lix1
|
limb and CNS expressed 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LIX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:66,802,272...66,860,627
|
|
G
|
Lman1
|
lectin, mannose-binding, 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LMAN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820
|
|
G
|
Lmf1
|
lipase maturation factor 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of LMF1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr10:15,094,432...15,188,665
Ensembl chr10:15,098,138...15,188,664
|
|
G
|
Lmo2
|
LIM domain only 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA panobinostat results in decreased expression of LMO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:110,810,162...110,832,895
Ensembl chr 3:110,809,912...110,833,075
|
|
G
|
Lmo3
|
LIM domain only 3
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LMO3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:172,965,951...173,025,156
|
|
G
|
Lmo7
|
LIM domain 7
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551
|
|
G
|
Lnx1
|
ligand of numb-protein X 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA panobinostat results in increased expression of LNX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217
|
|
G
|
Lpar6
|
lysophosphatidic acid receptor 6
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LPAR6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:54,826,110...54,827,919
Ensembl chr15:54,823,717...54,978,783
|
|
G
|
Lrig1
|
leucine-rich repeats and immunoglobulin-like domains 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LRIG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:128,687,723...128,788,219
Ensembl chr 4:128,687,723...128,788,219
|
|
G
|
Lrp12
|
LDL receptor related protein 12
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LRP12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:72,825,979...72,897,308
Ensembl chr 7:72,825,979...72,897,171
|
|
G
|
Lrp2
|
LDL receptor related protein 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA panobinostat results in decreased expression of LRP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535
|
|
G
|
Lrp8
|
LDL receptor related protein 8
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:127,792,299...127,864,207
|
|
G
|
Lrrc17
|
leucine rich repeat containing 17
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA panobinostat results in increased expression of LRRC17 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048
|
|
G
|
Lrrc3b
|
leucine rich repeat containing 3B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA panobinostat results in decreased expression of LRRC3B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:12,404,309...12,481,618
Ensembl chr15:12,336,369...12,481,866
|
|
G
|
Lrrc55
|
leucine rich repeat containing 55
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of LRRC55 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:90,676,547...90,687,392
Ensembl chr 3:90,680,160...90,685,280
|
|
G
|
Lrrc8b
|
leucine rich repeat containing 8 VRAC subunit B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA panobinostat results in decreased expression of LRRC8B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:4,655,273...4,721,648
Ensembl chr14:4,655,273...4,721,076
|
|
G
|
Lrrc8e
|
leucine rich repeat containing 8 VRAC subunit E
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA panobinostat results in increased expression of LRRC8E mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:7,376,103...7,387,250
Ensembl chr12:7,380,585...7,387,249
|
|
G
|
Lrrfip1
|
LRR binding FLII interacting protein 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:99,039,590...99,167,805
Ensembl chr 9:99,039,614...99,167,779
|
|
G
|
Lrrn3
|
leucine rich repeat neuronal 3
|
multiple interactions affects expression increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA] panobinostat affects the expression of LRRN3 mRNA panobinostat results in increased expression of LRRN3 mRNA
|
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 6:64,216,164...64,247,293
Ensembl chr 6:64,215,878...64,247,614
|
|
G
|
Lrrn4
|
leucine rich repeat neuronal 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:140,592,303...140,603,986
Ensembl chr 3:140,592,076...140,605,574
|
|
G
|
Lrrtm1
|
leucine rich repeat transmembrane neuronal 1
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA] panobinostat affects the expression of LRRTM1 mRNA
|
CTD |
PMID:26733615 PMID:27188386 |
|
NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818
|
|
G
|
Ly75
|
lymphocyte antigen 75
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LY75 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878
|
|
G
|
Lyn
|
LYN proto-oncogene, Src family tyrosine kinase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:21,437,084...21,554,461
|
|
G
|
Lypd3
|
Ly6/Plaur domain containing 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LYPD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:80,226,449...80,230,901
Ensembl chr 1:89,354,335...89,358,810
|
|
G
|
Lysmd2
|
LysM domain containing 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LYSMD2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,259,443...85,274,876
Ensembl chr 8:85,259,410...85,275,241
|
|
G
|
Lyzl6
|
lysozyme-like 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA panobinostat results in increased expression of LYZL6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:89,044,375...89,049,210
Ensembl chr10:89,044,375...89,049,210
|
|
G
|
Lzts1
|
leucine zipper tumor suppressor 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of LZTS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940
|
|
G
|
Mab21l2
|
mab-21 like 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of MAB21L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,244,538...174,247,620
Ensembl chr 2:174,238,828...174,252,064
|
|
G
|
Macc1
|
MET transcriptional regulator MACC1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA panobinostat results in increased expression of MACC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:146,495,861...146,574,260
|
|
G
|
Macrod2
|
mono-ADP ribosylhydrolase 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of MACROD2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:148,173,821...150,191,077
Ensembl chr 3:148,173,829...150,188,058
|
|
G
|
Macroh2a1
|
macroH2A.1 histone
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA Panobinostat results in decreased expression of MACROH2A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257
|
|
G
|
Mafb
|
MAF bZIP transcription factor B
|
increases expression
|
ISO
|
panobinostat results in increased expression of MAFB mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975
|
|
G
|
Magi2
|
membrane associated guanylate kinase, WW and PDZ domain containing 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA panobinostat results in increased expression of MAGI2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:15,278,518...16,762,427
Ensembl chr 4:15,278,518...16,762,199
|
|
G
|
Mak
|
male germ cell-associated kinase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA panobinostat results in decreased expression of MAK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855
|
|
G
|
Man1a1
|
mannosidase, alpha, class 1A, member 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MAN1A1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584
|
|
G
|
Maneal
|
mannosidase, endo-alpha-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA panobinostat results in increased expression of MANEAL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:137,115,154...137,122,299
Ensembl chr 5:142,400,213...142,407,027
|
|
G
|
Map2
|
microtubule-associated protein 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459
|
|
G
|
Map2k6
|
mitogen-activated protein kinase kinase 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721
|
|
G
|
Map6
|
microtubule-associated protein 6
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA panobinostat results in decreased expression of MAP6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:162,980,339...163,046,548
Ensembl chr 1:162,980,181...163,046,548
|
|
G
|
Map7d2
|
MAP7 domain containing 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:39,181,091...39,296,814
Ensembl chr X:39,181,091...39,296,695
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein
|
CTD |
PMID:18445700 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk10
|
mitogen activated protein kinase 10
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of MAPK10 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100
|
|
G
|
Mapk13
|
mitogen activated protein kinase 13
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA panobinostat results in increased expression of MAPK13 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein
|
CTD |
PMID:18445700 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mat1a
|
methionine adenosyltransferase 1A
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of MAT1A mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr16:17,017,168...17,035,368
Ensembl chr16:17,016,030...17,035,367
|
|
G
|
Mbnl3
|
muscleblind-like splicing regulator 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MBNL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:135,526,256...135,621,499
Ensembl chr X:135,532,494...135,621,976
|
|
G
|
Mboat1
|
membrane bound O-acyltransferase domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA panobinostat results in increased expression of MBOAT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698
|
|
G
|
Mcc
|
MCC regulator of WNT signaling pathway
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA panobinostat results in increased expression of MCC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:37,042,350...37,517,114
Ensembl chr18:37,049,253...37,517,076
|
|
G
|
Mcoln3
|
mucolipin TRP cation channel 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MCOLN3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:237,596,544...237,705,770
Ensembl chr 2:237,626,302...237,705,769
|
|
G
|
Mcub
|
mitochondrial calcium uniporter dominant negative subunit beta
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of MCUB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:221,153,525...221,223,814
|
|
G
|
Mdfic
|
MyoD family inhibitor domain containing
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA panobinostat results in increased expression of MDFIC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:44,938,301...45,018,157
Ensembl chr 4:44,938,480...45,018,156
|
|
G
|
Me3
|
malic enzyme 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA panobinostat results in decreased expression of ME3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:152,946,628...153,148,026
|
|
G
|
Mecom
|
MDS1 and EVI1 complex locus
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of MECOM mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 2:114,837,815...115,393,052
Ensembl chr 2:114,837,840...115,393,038
|
|
G
|
Med13l
|
mediator complex subunit 13L
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MED13L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:37,807,596...38,004,886
Ensembl chr12:43,468,556...43,665,819
|
|
G
|
Mef2c
|
myocyte enhancer factor 2C
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MEF2C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:15,708,924...15,871,640
|
|
G
|
Meis2
|
Meis homeobox 2
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MEIS2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MEIS2 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751
|
|
G
|
Meox1
|
mesenchyme homeobox 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA panobinostat results in increased expression of MEOX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976
|
|
G
|
Metrnl
|
meteorin-like, glial cell differentiation regulator
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA panobinostat results in increased expression of METRNL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135
|
|
G
|
Mettl21a
|
methyltransferase 21A, HSPA lysine
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:73,400,223...73,484,677
Ensembl chr 9:73,471,813...73,481,339
|
|
G
|
Mfap3l
|
microfibril associated protein 3 like
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA panobinostat results in decreased expression of MFAP3L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:34,422,490...34,465,544
Ensembl chr16:34,426,696...34,441,709
|
|
G
|
Mfng
|
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA panobinostat results in decreased expression of MFNG mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:112,191,288...112,209,129
Ensembl chr 7:112,161,071...112,209,129
|
|
G
|
Mgat3
|
beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of MGAT3 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 7:113,614,011...113,640,201
Ensembl chr 7:113,598,059...113,643,481
|
|
G
|
Mia
|
MIA SH3 domain containing
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MIA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:91,601,326...91,603,019
Ensembl chr 1:91,601,327...91,603,019
|
|
G
|
Miat
|
myocardial infarction associated transcript
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of MIAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:50,075,026...50,090,259
|
|
G
|
Micall1
|
MICAL-like 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MICALL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:112,557,192...112,587,618
|
|
G
|
Micb
|
MHC class I polypeptide-related sequence B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA Panobinostat results in increased expression of MICB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872
|
|
G
|
Mid1ip1
|
MID1 interacting protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MID1IP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:14,733,539...14,735,859
Ensembl chr X:14,732,830...14,739,079
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MMP14 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
G
|
Mnx1
|
motor neuron and pancreas homeobox 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MNX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:6,541,645...6,546,604
Ensembl chr 4:6,541,645...6,546,604
|
|
G
|
Mpped2
|
metallophosphoesterase domain containing 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA panobinostat results in decreased expression of MPPED2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:113,635,407...113,811,783
|
|
G
|
Mpz
|
myelin protein zero
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MPZ mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:86,103,290...86,109,156
Ensembl chr13:86,103,290...86,109,155
|
|
G
|
Msl1
|
MSL complex subunit 1
|
affects expression multiple interactions decreases expression
|
ISO
|
panobinostat affects the expression of MSL1 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MSL1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MSL1 mRNA] Panobinostat results in decreased expression of MSL1 mRNA
|
CTD |
PMID:26733615 PMID:33770205 |
|
NCBI chr10:84,251,362...84,263,384
Ensembl chr10:84,251,642...84,261,971
|
|
G
|
Msx1
|
msh homeobox 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA panobinostat results in increased expression of MSX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735
|
|
G
|
Msx2
|
msh homeobox 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA panobinostat results in increased expression of MSX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945
|
|
G
|
Mtarc2
|
mitochondrial amidoxime reducing component 2
|
increases expression multiple interactions
|
ISO
|
Panobinostat results in increased expression of MTARC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781
|
|
G
|
Mthfd2l
|
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MTHFD2L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:17,374,139...17,455,508
Ensembl chr14:17,374,144...17,454,322
|
|
G
|
Muc15
|
mucin 15, cell surface associated
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MUC15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:117,749,161...117,761,466
Ensembl chr 3:117,749,324...117,762,101
|
|
G
|
Muc3a
|
mucin 3A, cell surface associated
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr12:25,082,728...25,091,494
Ensembl chr12:25,082,837...25,097,265
|
|
G
|
Muc4
|
mucin 4, cell surface associated
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA panobinostat results in increased expression of MUC4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:81,513,321...81,575,200
|
|
G
|
Mustn1
|
musculoskeletal, embryonic nuclear protein 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586
|
|
G
|
Mvb12a
|
multivesicular body subunit 12A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA panobinostat results in decreased expression of MVB12A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:18,286,231...18,291,096
Ensembl chr16:18,286,231...18,292,583
|
|
G
|
Mxra7
|
matrix remodeling associated 7
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA panobinostat results in decreased expression of MXRA7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:102,501,848...102,530,231
Ensembl chr10:102,489,604...102,530,231
|
|
G
|
Mybl1
|
MYB proto-oncogene like 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of MYBL1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat results in decreased expression of MYC protein]; [panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of MYC protein; panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]; panobinostat promotes the reaction [SRT2183 results in decreased expression of MYC protein]
|
CTD |
PMID:23681230 PMID:24435446 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Mycn
|
MYCN proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of MYCN protein]; [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; Panobinostat inhibits the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein] panobinostat results in decreased expression of MYCN protein panobinostat results in increased expression of MYCN mRNA
|
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508
|
|
G
|
Myct1
|
myc target 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:44,423,478...44,434,751
Ensembl chr 1:44,423,544...44,436,992
|
|
G
|
Myf5
|
myogenic factor 5
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:44,689,407...44,692,638
Ensembl chr 7:44,689,407...44,692,638
|
|
G
|
Mylip
|
myosin regulatory light chain interacting protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA panobinostat results in increased expression of MYLIP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471
|
|
G
|
Mylk
|
myosin light chain kinase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA panobinostat results in decreased expression of MYLK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659
|
|
G
|
Myo1d
|
myosin ID
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA panobinostat results in increased expression of MYO1D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958
|
|
G
|
Myo1e
|
myosin IE
|
increases expression
|
ISO
|
Panobinostat results in increased expression of MYO1E mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 8:79,768,828...79,961,048
Ensembl chr 8:79,753,596...79,961,045
|
|
G
|
Myo5b
|
myosin Vb
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr18:70,313,717...70,613,918
Ensembl chr18:70,311,990...70,613,918
|
|
G
|
Myocd
|
myocardin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MYOCD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819
|
|
G
|
Myof
|
myoferlin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of MYOF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768
|
|
G
|
Nabp1
|
nucleic acid binding protein 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NABP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052
|
|
G
|
Nalf1
|
NALCN channel auxiliary factor 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA Panobinostat results in decreased expression of NALF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150
|
|
G
|
Nanog
|
Nanog homeobox
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NANOG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061
|
|
G
|
Nanos1
|
nanos C2HC-type zinc finger 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA panobinostat results in decreased expression of NANOS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417
|
|
G
|
Nans
|
N-acetylneuraminate synthase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA panobinostat results in increased expression of NANS mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:65,576,015...65,610,547
|
|
G
|
Nav1
|
neuron navigator 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA panobinostat results in decreased expression of NAV1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:49,418,755...49,671,117
Ensembl chr13:49,418,755...49,671,004
|
|
G
|
Nav3
|
neuron navigator 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA panobinostat results in increased expression of NAV3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893
|
|
G
|
Ncald
|
neurocalcin delta
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA panobinostat results in decreased expression of NCALD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,417,683...70,849,763
Ensembl chr 7:70,419,433...70,849,482
|
|
G
|
Ncoa7
|
nuclear receptor coactivator 7
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA panobinostat results in decreased expression of NCOA7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886
|
|
G
|
Ndp
|
norrin cystine knot growth factor NDP
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA panobinostat results in decreased expression of NDP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:8,379,569...8,404,019
Ensembl chr X:8,379,569...8,406,802
|
|
G
|
Ndufb1
|
NADH:ubiquinone oxidoreductase subunit B1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of NDUFB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:121,115,649...121,124,055
Ensembl chr 6:126,880,537...126,888,864
|
|
G
|
Nefl
|
neurofilament light chain
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NEFL mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515
|
|
G
|
Nefm
|
neurofilament medium chain
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA panobinostat results in increased expression of NEFM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163
|
|
G
|
Negr1
|
neuronal growth regulator 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of NEGR1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:248,283,164...249,015,538
Ensembl chr 2:248,283,353...249,018,410
|
|
G
|
Nell1
|
neural EGFL like 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NELL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:108,845,462...109,709,858
Ensembl chr 1:108,845,462...109,709,858
|
|
G
|
Nell2
|
neural EGFL like 2
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of NELL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917
|
|
G
|
Neu1
|
neuraminidase 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of NEU1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383
|
|
G
|
Neurl3
|
neuralized E3 ubiquitin protein ligase 3
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of LINCR mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 9:45,990,373...45,998,470
Ensembl chr 9:45,990,375...45,998,535
|
|
G
|
Nexmif
|
neurite extension and migration factor
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA panobinostat results in decreased expression of NEXMIF mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:73,153,786...73,284,943
Ensembl chr X:73,153,786...73,178,639
|
|
G
|
Nf1
|
neurofibromin 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of NF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,804,266...65,034,946
|
|
G
|
Nfasc
|
neurofascin
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA panobinostat results in decreased expression of NFASC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:46,549,369...46,735,989
Ensembl chr13:46,549,369...46,736,139
|
|
G
|
Nfatc4
|
nuclear factor of activated T-cells 4
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of NFATC4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:33,256,912...33,284,522
Ensembl chr15:33,274,153...33,285,582
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NFE2L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfib
|
nuclear factor I/B
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NFIB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:101,805,168...102,020,618
Ensembl chr 5:101,805,168...102,019,945
|
|
G
|
Nfic
|
nuclear factor I/C
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NFIC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NFIC mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 7:8,928,423...8,963,455
Ensembl chr 7:8,904,117...8,963,409
|
|
G
|
Ngef
|
neuronal guanine nucleotide exchange factor
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NGEF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251
|
|
G
|
Ngfr
|
nerve growth factor receptor
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NGFR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305
|
|
G
|
Nhsl2
|
NHS-like 2
|
affects expression multiple interactions
|
ISO
|
panobinostat affects the expression of NHSL2 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NHSL2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NHSL2 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr X:71,009,940...71,249,427
Ensembl chr X:71,009,949...71,241,289
|
|
G
|
Nipal2
|
NIPA-like domain containing 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NIPAL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:67,659,628...67,771,105
Ensembl chr 7:67,659,628...67,769,959
|
|
G
|
Nkain3
|
Sodium/potassium transporting ATPase interacting 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA Panobinostat results in decreased expression of NKAIN3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:38,410,576...39,106,910
Ensembl chr 5:38,386,841...39,106,385
|
|
G
|
Nkd1
|
NKD inhibitor of WNT signaling pathway 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NKD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,649,803...34,722,846
|
|
G
|
Nlgn1
|
neuroligin 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of NLGN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984
|
|
G
|
Nlrp1a
|
NLR family, pyrin domain containing 1A
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of NLRP1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880
|
|
G
|
Nme8
|
NME/NM23 family member 8
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NME8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:49,932,861...50,000,610
Ensembl chr17:49,932,860...50,000,608
|
|
G
|
Nmi
|
N-myc (and STAT) interactor
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of NMI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717
|
|
G
|
Nmnat2
|
nicotinamide nucleotide adenylyltransferase 2
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA panobinostat results in increased expression of NMNAT2 mRNA
|
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr13:67,655,794...67,831,609
Ensembl chr13:67,655,807...67,831,608
|
|
G
|
Noct
|
nocturnin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA panobinostat results in increased expression of NOCT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282
|
|
G
|
Nog
|
noggin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00472 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1LC3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VHRT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA panobinostat results in increased expression of NOG mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103
|
|
G
|
Nol4
|
nucleolar protein 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA panobinostat results in decreased expression of NOL4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:14,207,303...14,569,697
Ensembl chr18:14,207,303...14,569,677
|
|
G
|
Npffr2
|
neuropeptide FF receptor 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA panobinostat results in increased expression of NPFFR2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:18,513,120...18,558,074
Ensembl chr14:18,797,234...18,842,186
|
|
G
|
Npnt
|
nephronectin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA panobinostat results in increased expression of NPNT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:224,065,191...224,133,435
|
|
G
|
Npr3
|
natriuretic peptide receptor 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA panobinostat results in increased expression of NPR3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:62,592,557...62,660,497
Ensembl chr 2:62,597,668...62,660,066
|
|
G
|
Npy
|
neuropeptide Y
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA panobinostat results in increased expression of NPY mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310
|
|
G
|
Npy1r
|
neuropeptide Y receptor Y1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA panobinostat results in decreased expression of NPY1R mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387
|
|
G
|
Npy2r
|
neuropeptide Y receptor Y2
|
multiple interactions affects expression decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of NPY2R mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA] panobinostat affects the expression of NPY2R mRNA panobinostat results in decreased expression of NPY2R mRNA
|
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 2:170,200,027...170,210,286
Ensembl chr 2:170,200,027...170,210,448
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA panobinostat results in increased expression of NQO1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nqo2
|
N-ribosyldihydronicotinamide:quinone dehydrogenase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA panobinostat results in increased expression of NQO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662
|
|
G
|
Nr2f1
|
nuclear receptor subfamily 2, group F, member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA panobinostat results in increased expression of NR2F1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924
|
|
G
|
Nr2f2
|
nuclear receptor subfamily 2, group F, member 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA panobinostat results in decreased expression of NR2F2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975
|
|
G
|
Nrg1
|
neuregulin 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA panobinostat results in decreased expression of NRG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849
|
|
G
|
Nrip1
|
nuclear receptor interacting protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA panobinostat results in increased expression of NRIP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353
|
|
G
|
Nrip3
|
nuclear receptor interacting protein 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA panobinostat results in decreased expression of NRIP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:173,224,532...173,249,829
Ensembl chr 1:173,224,532...173,251,769
|
|
G
|
Nrk
|
Nik related kinase
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:107,159,154...107,256,417
Ensembl chr X:107,159,233...107,256,417
|
|
G
|
Nrp1
|
neuropilin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA panobinostat results in increased expression of NRP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702
|
|
G
|
Nrp2
|
neuropilin 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871
|
|
G
|
Nrros
|
negative regulator of reactive oxygen species
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of NRROS mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr11:82,133,608...82,151,160
Ensembl chr11:82,133,144...82,151,308
|
|
G
|
Nrxn2
|
neurexin 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:213,155,673...213,271,526
Ensembl chr 1:213,155,673...213,271,526
|
|
G
|
Nsd2
|
nuclear receptor binding SET domain protein 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA panobinostat results in decreased expression of NSD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:81,057,727...81,135,866
Ensembl chr14:81,057,727...81,123,027
|
|
G
|
Nsmaf
|
neutral sphingomyelinase activation associated factor
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NSMAF mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NSMAF mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 5:24,315,319...24,378,346
Ensembl chr 5:24,315,319...24,375,355
|
|
G
|
Ntn4
|
netrin 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA panobinostat results in decreased expression of NTN4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:30,073,637...30,187,407
Ensembl chr 7:30,073,333...30,188,309
|
|
G
|
Nuak2
|
NUAK family kinase 2
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of NUAK2 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr13:46,305,744...46,322,755
Ensembl chr13:46,305,975...46,322,748
|
|
G
|
Nudt4
|
nudix hydrolase 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA panobinostat results in increased expression of NUDT4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491
|
|
G
|
Nwd2
|
NACHT and WD repeat domain containing 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA panobinostat results in increased expression of NWD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:44,833,623...45,024,962
Ensembl chr14:44,834,856...45,024,047
|
|
G
|
Oat
|
ornithine aminotransferase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA panobinostat results in increased expression of OAT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754
|
|
G
|
Ola1
|
Obg-like ATPase 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA panobinostat results in decreased expression of OLA1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:78,374,440...78,493,401
Ensembl chr 3:78,374,441...78,492,012
|
|
G
|
Olfm3
|
olfactomedin 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA panobinostat results in increased expression of OLFM3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:205,417,962...205,640,479
Ensembl chr 2:205,598,959...205,640,479
|
|
G
|
Olfml3
|
olfactomedin-like 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA panobinostat results in increased expression of OLFML3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:193,932,665...193,935,494
|
|
G
|
Olig3
|
oligodendrocyte transcription factor 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274
|
|
G
|
Onecut2
|
one cut homeobox 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of ONECUT2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668
|
|
G
|
Opcml
|
opioid binding protein/cell adhesion molecule-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA panobinostat results in increased expression of OPCML mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:34,451,629...35,562,897
Ensembl chr 8:34,451,500...35,558,966
|
|
G
|
Oprk1
|
opioid receptor, kappa 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA panobinostat results in decreased expression of OPRK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671
|
|
G
|
Orm1
|
orosomucoid 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA panobinostat results in decreased expression of ORM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667
|
|
G
|
Osbpl10
|
oxysterol binding protein-like 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA panobinostat results in increased expression of OSBPL10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:123,536,818...123,796,822
Ensembl chr 8:123,539,235...123,796,822
|
|
G
|
Otx2
|
orthodenticle homeobox 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:24,422,876...24,432,709
Ensembl chr15:24,422,876...24,432,472
|
|
G
|
Ovol1
|
ovo like transcriptional repressor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA panobinostat results in increased expression of OVOL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:212,284,601...212,296,106
Ensembl chr 1:212,284,605...212,296,106
|
|
G
|
Ovol2
|
ovo-like zinc finger 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:152,130,767...152,160,487
Ensembl chr 3:152,130,767...152,160,487
|
|
G
|
Pabpc4l
|
poly(A) binding protein, cytoplasmic 4-like
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PABPC4L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:129,807,755...129,809,745
Ensembl chr 2:131,740,252...131,746,176
|
|
G
|
Pabpc5
|
poly A binding protein, cytoplasmic 5
|
increases expression
|
ISO
|
panobinostat results in increased expression of PABPC5 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr X:85,637,763...85,641,235
Ensembl chr X:89,858,427...89,860,487
|
|
G
|
Pak3
|
p21 (RAC1) activated kinase 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA panobinostat results in decreased expression of PAK3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:111,912,967...112,171,037
Ensembl chr X:111,913,059...112,165,035
|
|
G
|
Pamr1
|
peptidase domain containing associated with muscle regeneration 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA panobinostat results in decreased expression of PAMR1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:109,340,411...109,443,595
Ensembl chr 3:109,341,476...109,443,585
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
[resveratrol co-treated with panobinostat] results in increased cleavage of PARP1 protein
|
CTD |
PMID:22923501 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Patj
|
PATJ, crumbs cell polarity complex component
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:118,177,565...118,480,301
|
|
G
|
Pax2
|
paired box 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA panobinostat results in increased expression of PAX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:253,555,447...253,646,623
Ensembl chr 1:253,555,418...253,645,438
|
|
G
|
Pax3
|
paired box 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA panobinostat results in increased expression of PAX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141
|
|
G
|
Pax6
|
paired box 6
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of PAX6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763
|
|
G
|
Pax7
|
paired box 7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PAX7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:157,279,623...157,381,188
Ensembl chr 5:157,279,623...157,381,121
|
|
G
|
Pbx2
|
PBX homeobox 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of PBX2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr20:4,156,107...4,161,503
Ensembl chr20:4,156,107...4,161,827
|
|
G
|
Pcdh10
|
protocadherin 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA panobinostat results in increased expression of PCDH10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:130,553,425...130,613,407
|
|
G
|
Pcdh20
|
protocadherin 20
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA panobinostat results in increased expression of PCDH20 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:70,834,042...70,840,298
Ensembl chr15:70,834,042...70,840,298
|
|
G
|
Pcdh7
|
protocadherin 7
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA panobinostat results in increased expression of PCDH7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:56,684,817...57,114,976
Ensembl chr14:56,687,725...57,112,665
|
|
G
|
Pcdh8
|
protocadherin 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA panobinostat results in increased expression of PCDH8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:61,607,521...61,612,090
Ensembl chr15:61,607,521...61,612,097
|
|
G
|
Pcdhb20
|
protocadherin beta 20
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA panobinostat results in decreased expression of PCDHB14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,454,999...29,489,427
|
|
G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561
|
|
G
|
Pcm1
|
pericentriolar material 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:57,711,833...57,808,842
Ensembl chr16:57,711,833...57,808,599
|
|
G
|
Pcmtd1
|
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:17,071,629...17,143,803
Ensembl chr 5:17,071,629...17,142,010
|
|
G
|
Pcolce
|
procollagen C-endopeptidase enhancer
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr12:24,720,972...24,727,287
Ensembl chr12:24,720,936...24,727,287
|
|
G
|
Pcolce2
|
procollagen C-endopeptidase enhancer 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA panobinostat results in increased expression of PCOLCE2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:105,073,086...105,130,725
Ensembl chr 8:105,073,086...105,145,160
|
|
G
|
Pcp4l1
|
Purkinje cell protein 4-like 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr13:86,121,463...86,145,097
Ensembl chr13:86,121,464...86,144,899
|
|
G
|
Pde10a
|
phosphodiesterase 10A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA panobinostat results in decreased expression of PDE10A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:54,317,732...54,764,051
|
|
G
|
Pde11a
|
phosphodiesterase 11A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:81,320,822...81,680,612
|
|
G
|
Pde3a
|
phosphodiesterase 3A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA panobinostat results in increased expression of PDE3A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270
|
|
G
|
Pde4c
|
phosphodiesterase 4C
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of PDE4C mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr16:18,724,703...18,745,528
Ensembl chr16:18,725,674...18,744,037
|
|
G
|
Pde4d
|
phosphodiesterase 4D
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA panobinostat results in increased expression of PDE4D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:41,748,337...43,262,567
Ensembl chr 2:42,110,838...43,262,569
|
|
G
|
Pde4dip
|
phosphodiesterase 4D interacting protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA panobinostat results in increased expression of PDE4DIP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869
|
|
G
|
Pdgfa
|
platelet derived growth factor subunit A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA panobinostat results in increased expression of PDGFA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322
|
|
G
|
Pdgfc
|
platelet derived growth factor C
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PDGFC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:168,613,409...168,791,575
Ensembl chr 2:168,614,353...168,791,573
|
|
G
|
Pdgfra
|
platelet derived growth factor receptor alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA panobinostat results in increased expression of PDGFRA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516
|
|
G
|
Pdia5
|
protein disulfide isomerase family A, member 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA panobinostat results in increased expression of PDIA5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329
|
|
G
|
Pdlim1
|
PDZ and LIM domain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA panobinostat results in increased expression of PDLIM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379
|
|
G
|
Pdpn
|
podoplanin
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PDPN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637
|
|
G
|
Pdyn
|
prodynorphin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA panobinostat results in increased expression of PDYN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:137,354,161...137,366,503
|
|
G
|
Pfkp
|
phosphofructokinase, platelet
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PFKP mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:68,639,749...68,704,055
Ensembl chr17:68,639,481...68,705,752
|
|
G
|
Pgcka1
|
PDCD10 and GCKIII kinases associated 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,740,972...44,831,613
|
|
G
|
Pgm1
|
phosphoglucomutase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA panobinostat results in increased expression of PGM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:119,710,737...119,770,159
|
|
G
|
Phip
|
pleckstrin homology domain interacting protein
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA panobinostat results in decreased expression of PHIP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:92,656,890...92,771,098
Ensembl chr 8:92,656,890...92,771,021
|
|
G
|
Phlda1
|
pleckstrin homology-like domain, family A, member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA panobinostat results in increased expression of PHLDA1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542
|
|
G
|
Phlda2
|
pleckstrin homology-like domain, family A, member 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PHLDA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920
|
|
G
|
Phtf2
|
putative homeodomain transcription factor 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 4:15,107,341...15,222,683
Ensembl chr 4:15,107,373...15,222,692
|
|
G
|
Pid1
|
phosphotyrosine interaction domain containing 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:92,734,214...92,750,070
|
|
G
|
Piezo2
|
piezo-type mechanosensitive ion channel component 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr18:58,738,734...59,115,252
Ensembl chr18:58,738,740...59,115,215
|
|
G
|
Pim1
|
Pim-1 proto-oncogene, serine/threonine kinase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PIM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764
|
|
G
|
Pipox
|
pipecolic acid and sarcosine oxidase
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PIPOX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:63,267,946...63,281,556
Ensembl chr10:63,267,972...63,282,273
|
|
G
|
Pitx2
|
paired-like homeodomain 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA panobinostat results in increased expression of PITX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:220,391,888...220,411,591
|
|
G
|
Pkdcc
|
protein kinase domain containing, cytoplasmic
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PKDCC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:17,208,171...17,217,488
Ensembl chr 6:17,208,171...17,218,042
|
|
G
|
Pkm
|
pyruvate kinase M1/2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of PKM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396
|
|
G
|
Pknox2
|
PBX/knotted 1 homeobox 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA panobinostat results in increased expression of PKNOX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:44,789,464...45,051,933
Ensembl chr 8:44,789,467...44,979,754
|
|
G
|
Pla2g2a
|
phospholipase A2 group IIA
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA panobinostat results in increased expression of PLA2G2A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA panobinostat results in increased expression of PLA2G4A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
G
|
Pla2g7
|
phospholipase A2 group VII
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA panobinostat results in increased expression of PLA2G7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747
|
|
G
|
Plaat5
|
phospholipase A and acyltransferase 5
|
increases expression multiple interactions
|
ISO
|
Panobinostat results in increased expression of PLAAT5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:204,847,600...204,878,456
Ensembl chr 1:214,277,044...214,307,598
|
|
G
|
Plat
|
plasminogen activator, tissue type
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA panobinostat results in increased expression of PLAT mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA panobinostat results in increased expression of PLAU mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Plbd1
|
phospholipase B domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA panobinostat results in increased expression of PLBD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488
|
|
G
|
Plce1
|
phospholipase C, epsilon 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA panobinostat results in increased expression of PLCE1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828
|
|
G
|
Plekha2
|
pleckstrin homology domain containing A2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr16:73,641,338...73,704,068
Ensembl chr16:73,641,344...73,703,087
|
|
G
|
Plekhm3
|
pleckstrin homology domain containing M3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:73,659,998...73,819,079
Ensembl chr 9:73,664,817...73,799,503
|
|
G
|
Plod2
|
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA panobinostat results in increased expression of PLOD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022
|
|
G
|
Plp1
|
proteolipid protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA panobinostat results in increased expression of PLP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
G
|
Plscr1
|
phospholipid scramblase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA panobinostat results in increased expression of PLSCR1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:101,662,512...101,684,474
Ensembl chr 8:101,664,056...101,684,614
|
|
G
|
Plxna2
|
plexin A2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA panobinostat results in increased expression of PLXNA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453
|
|
G
|
Plxnc1
|
plexin C1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA panobinostat results in decreased expression of PLXNC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:31,276,978...31,431,092
|
|
G
|
Pmepa1
|
prostate transmembrane protein, androgen induced 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA panobinostat results in increased expression of PMEPA1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:182,430,193...182,478,649
|
|
G
|
Pnmt
|
phenylethanolamine-N-methyltransferase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of PNMT mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr10:83,881,211...83,882,849
Ensembl chr10:83,881,185...83,882,849
|
|
G
|
Pnp
|
purine nucleoside phosphorylase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA panobinostat results in increased expression of PNP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:26,644,147...26,651,808
Ensembl chr15:26,643,858...26,678,162
|
|
G
|
Podxl
|
podocalyxin-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA panobinostat results in increased expression of PODXL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789
|
|
G
|
Poli
|
DNA polymerase iota
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA panobinostat results in decreased expression of POLI mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:66,389,214...66,409,734
Ensembl chr18:66,364,236...66,409,819
|
|
G
|
Polr2a
|
RNA polymerase II subunit A
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased phosphorylation of POLR2A protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of POLR2A protein] panobinostat results in decreased phosphorylation of POLR2A protein
|
CTD |
PMID:24435446 |
|
NCBI chr10:54,951,162...54,977,179
Ensembl chr10:54,951,162...54,977,179
|
|
G
|
Polr3e
|
RNA polymerase III subunit E
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of POLR3E mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:184,897,426...184,926,534
|
|
G
|
Polr3g
|
RNA polymerase III subunit G
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA panobinostat results in increased expression of POLR3G mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:13,680,893...13,721,802
Ensembl chr 2:13,680,895...13,721,802
|
|
G
|
Pon1
|
paraoxonase 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA panobinostat results in decreased expression of PON1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924
|
|
G
|
Popdc2
|
popeye domain cAMP effector 2
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of POPDC2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of POPDC2 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr11:75,850,068...75,897,094
Ensembl chr11:75,880,274...75,896,269
|
|
G
|
Popdc3
|
popeye domain cAMP effector 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA panobinostat results in decreased expression of POPDC3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:50,354,775...50,383,050
Ensembl chr20:50,354,767...50,385,674
|
|
G
|
Pou3f1
|
POU class 3 homeobox 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA panobinostat results in decreased expression of POU3F1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:142,195,090...142,198,070
Ensembl chr 5:142,194,066...142,202,704
|
|
G
|
Pou3f3
|
POU class 3 homeobox 3
|
increases expression
|
ISO
|
panobinostat results in increased expression of POU3F3 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 9:52,438,026...52,441,152
Ensembl chr 9:52,435,625...52,454,705
|
|
G
|
Pou5f1
|
POU class 5 homeobox 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of POU5F1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598
|
|
G
|
Ppargc1b
|
PPARG coactivator 1 beta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA panobinostat results in increased expression of PPARGC1B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:57,029,264...57,131,466
Ensembl chr18:57,029,275...57,131,466
|
|
G
|
Ppib
|
peptidylprolyl isomerase B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA panobinostat results in increased expression of PPIB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:75,498,966...75,504,823
Ensembl chr 8:75,498,797...75,504,847
|
|
G
|
Ppic
|
peptidylprolyl isomerase C
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA panobinostat results in increased expression of PPIC mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:49,040,690...49,053,296
Ensembl chr18:49,040,692...49,053,466
|
|
G
|
Ppl
|
periplakin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA panobinostat results in increased expression of PPL mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:10,957,388...11,003,035
Ensembl chr10:10,957,341...11,003,658
|
|
G
|
Ppm1a
|
protein phosphatase, Mg2+/Mn2+ dependent, 1A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 6:97,174,955...97,216,585
Ensembl chr 6:97,174,916...97,216,574
|
|
G
|
Ppm1j
|
protein phosphatase, Mg2+/Mn2+ dependent, 1J
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA panobinostat results in increased expression of PPM1J mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:194,966,854...194,972,228
Ensembl chr 2:194,966,950...194,972,227
|
|
G
|
Ppm1k
|
protein phosphatase, Mg2+/Mn2+ dependent, 1K
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA panobinostat results in increased expression of PPM1K mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:88,942,386...88,969,136
|
|
G
|
Ppox
|
protoporphyrinogen oxidase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA panobinostat results in decreased expression of PPOX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:86,230,111...86,235,028
Ensembl chr13:86,230,111...86,234,246
|
|
G
|
Ppp1r13l
|
protein phosphatase 1, regulatory subunit 13 like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA panobinostat results in increased expression of PPP1R13L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:88,139,000...88,158,714
Ensembl chr 1:88,140,532...88,158,714
|
|
G
|
Ppp1r1a
|
protein phosphatase 1, regulatory (inhibitor) subunit 1A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA panobinostat results in increased expression of PPP1R1A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:136,533,031...136,540,687
Ensembl chr 7:136,523,604...136,540,683
|
|
G
|
Ppp1r3b
|
protein phosphatase 1, regulatory subunit 3B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA panobinostat results in increased expression of PPP1R3B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:63,533,318...63,545,683
Ensembl chr16:63,532,842...63,549,997
|
|
G
|
Ppp1r3d
|
protein phosphatase 1, regulatory subunit 3D
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA panobinostat results in increased expression of PPP1R3D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:185,880,087...185,883,158
Ensembl chr 3:185,876,709...185,883,703
|
|
G
|
Ppp1r9a
|
protein phosphatase 1, regulatory subunit 9A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA panobinostat results in decreased expression of PPP1R9A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:33,936,949...34,258,927
Ensembl chr 4:33,988,827...34,258,927
|
|
G
|
Ppp2r2b
|
protein phosphatase 2, regulatory subunit B, beta
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA panobinostat results in decreased expression of PPP2R2B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,904,686...35,356,977
|
|
G
|
Prag1
|
PEAK1 related kinase activating pseudokinase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA panobinostat results in increased expression of PRAG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532
|
|
G
|
Prdm1
|
PR/SET domain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA panobinostat results in increased expression of PRDM1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:49,542,465...49,564,088
Ensembl chr20:49,542,465...49,564,088
|
|
G
|
Prdm14
|
PR/SET domain 14
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA panobinostat results in increased expression of PRDM14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:10,864,137...10,876,666
Ensembl chr 5:10,864,137...10,876,666
|
|
G
|
Prdm16
|
PR/SET domain 16
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:170,162,275...170,486,371
Ensembl chr 5:170,162,275...170,485,804
|
|
G
|
Prelp
|
proline and arginine rich end leucine rich repeat protein
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr13:47,920,480...47,943,547
Ensembl chr13:47,922,590...47,932,324
|
|
G
|
Prex1
|
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA panobinostat results in increased expression of PREX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:175,724,939...175,875,764
Ensembl chr 3:175,726,012...175,875,764
|
|
G
|
Prkaca
|
protein kinase cAMP-activated catalytic subunit alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA panobinostat results in increased expression of PRKACA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494
|
|
G
|
Prkca
|
protein kinase C, alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA panobinostat results in increased expression of PRKCA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572
|
|
G
|
Prkcb
|
protein kinase C, beta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA panobinostat results in increased expression of PRKCB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740
|
|
G
|
Prkch
|
protein kinase C, eta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA panobinostat results in increased expression of PRKCH mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:98,027,830...98,226,486
Ensembl chr 6:98,027,646...98,226,477
|
|
G
|
Prnp
|
prion protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA panobinostat results in increased expression of PRNP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436
|
|
G
|
Prodh
|
proline dehydrogenase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA panobinostat results in increased expression of PRODH mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:96,414,275...96,431,604
Ensembl chr11:96,414,224...96,433,418
|
|
G
|
Prok2
|
prokineticin 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA panobinostat results in decreased expression of PROK2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:133,903,210...133,918,126
Ensembl chr 4:133,903,210...133,917,933
|
|
G
|
Prr15
|
proline rich 15
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA panobinostat results in increased expression of PRR15 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:84,762,357...84,765,403
Ensembl chr 4:84,761,523...84,768,442
|
|
G
|
Prr16
|
proline rich 16
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA panobinostat results in increased expression of PRR16 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:44,424,348...44,764,796
Ensembl chr18:46,623,058...46,830,385
|
|
G
|
Prrg1
|
proline rich and Gla domain 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA panobinostat results in increased expression of PRRG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:46,381,329...46,493,677
Ensembl chr X:46,383,967...46,493,700
|
|
G
|
Prrx1
|
paired related homeobox 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA panobinostat results in increased expression of PRRX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:78,136,783...78,205,379
Ensembl chr13:78,136,783...78,204,058
|
|
G
|
Prss12
|
serine protease 12
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA panobinostat results in increased expression of PRSS12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941
|
|
G
|
Prss23
|
serine protease 23
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA panobinostat results in decreased expression of PRSS23 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871
|
|
G
|
Prss8
|
serine protease 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA panobinostat results in increased expression of PRSS8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:191,966,701...191,971,271
Ensembl chr 1:191,966,701...191,971,193
|
|
G
|
Prune2
|
prune homolog 2 with BCH domain
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA panobinostat results in decreased expression of PRUNE2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592
|
|
G
|
Ptchd1
|
patched domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA panobinostat results in increased expression of PTCHD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:43,496,907...43,548,413
Ensembl chr X:43,496,907...43,548,544
|
|
G
|
Ptger4
|
prostaglandin E receptor 4
|
increases expression
|
ISO
|
panobinostat results in increased expression of PTGER4 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA panobinostat results in decreased expression of PTGS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptpn5
|
protein tyrosine phosphatase, non-receptor type 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA panobinostat results in decreased expression of PTPN5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:106,756,896...106,816,828
|
|
G
|
Ptpn9
|
protein tyrosine phosphatase, non-receptor type 9
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of PTPN9 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of PTPN9 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 8:66,286,771...66,368,306
Ensembl chr 8:66,287,284...66,368,294
|
|
G
|
Ptprf
|
protein tyrosine phosphatase, receptor type, F
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of PTPRF mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426
|
|
G
|
Ptprn2
|
protein tyrosine phosphatase, receptor type N2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA panobinostat results in decreased expression of PTPRN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:143,582,568...144,334,573
Ensembl chr 6:143,582,547...144,336,744
|
|
G
|
Ptpro
|
protein tyrosine phosphatase, receptor type, O
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA panobinostat results in decreased expression of PTPRO mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903
|
|
G
|
Purg
|
purine-rich element binding protein G
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA panobinostat results in decreased expression of PURG mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:65,435,371...65,466,437
Ensembl chr16:65,412,238...65,466,185
|
|
G
|
Pwwp2b
|
PWWP domain containing 2B
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:203,470,172...203,489,575
Ensembl chr 1:203,470,928...203,489,549
|
|
G
|
Pxdc1
|
PX domain containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA panobinostat results in increased expression of PXDC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:30,481,336...30,510,330
Ensembl chr17:30,481,373...30,510,331
|
|
G
|
Pycard
|
PYD and CARD domain containing
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA panobinostat results in increased expression of PYCARD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419
|
|
G
|
Pym1
|
PYM homolog 1, exon junction complex associated factor
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of PYM1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 7:1,177,746...1,200,899
Ensembl chr 7:1,759,110...1,783,948
|
|
G
|
Rab11fip1
|
RAB11 family interacting protein 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of RAB11FIP1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr16:71,589,753...71,620,341
Ensembl chr16:71,589,753...71,620,341
|
|
G
|
Rab11fip4
|
RAB11 family interacting protein 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA panobinostat results in increased expression of RAB11FIP4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:65,048,070...65,156,086
Ensembl chr10:65,048,140...65,152,722
|
|
G
|
Rab17
|
RAB17, member RAS oncogene family
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA panobinostat results in increased expression of RAB17 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:99,001,044...99,014,340
Ensembl chr 9:99,001,045...99,014,032
|
|
G
|
Rab20
|
RAB20, member RAS oncogene family
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA panobinostat results in increased expression of RAB20 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:84,721,427...84,745,610
Ensembl chr16:84,721,427...84,745,610
|
|
G
|
Rab31
|
RAB31, member RAS oncogene family
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA panobinostat results in increased expression of RAB31 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092
|
|
G
|
Rab33a
|
RAB33A, member RAS oncogene family
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA panobinostat results in decreased expression of RAB33A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:132,572,133...132,584,255
Ensembl chr X:132,572,148...132,584,254
|
|
G
|
Rab3c
|
RAB3C, member RAS oncogene family
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA panobinostat results in increased expression of RAB3C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:43,361,093...43,577,022
|
|
G
|
Rab3ip
|
RAB3A interacting protein
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA panobinostat results in decreased expression of RAB3IP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:54,417,418...54,461,253
Ensembl chr 7:54,418,358...54,447,000
|
|
G
|
Rab7b
|
Rab7b, member RAS oncogene family
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA panobinostat results in increased expression of RAB7B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:45,673,396...45,699,798
Ensembl chr13:45,673,416...45,709,933
|
|
G
|
Rabgap1l
|
RAB GTPase activating protein 1-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA panobinostat results in increased expression of RABGAP1L mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:74,997,542...75,593,240
Ensembl chr13:74,997,542...75,533,816
|
|
G
|
Rac2
|
Rac family small GTPase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA panobinostat results in increased expression of RAC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267
|
|
G
|
Raf1
|
Raf-1 proto-oncogene, serine/threonine kinase
|
multiple interactions
|
ISO
|
[Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein
|
CTD |
PMID:18445700 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813
|
|
G
|
Ralgdsl1
|
ral guanine nucleotide dissociation stimulator like 1
|
increases expression
|
ISO
|
Panobinostat results in increased expression of RGL1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr13:67,184,402...67,454,019
Ensembl chr13:67,184,402...67,454,019
|
|
G
|
Rarb
|
retinoic acid receptor, beta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA panobinostat results in increased expression of RARB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040
|
|
G
|
Rarres2
|
retinoic acid receptor responder 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA panobinostat results in increased expression of RARRES2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457
|
|
G
|
Rasa2
|
RAS p21 protein activator 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA panobinostat results in decreased expression of RASA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:105,996,797...106,116,285
Ensembl chr 8:106,000,002...106,116,206
|
|
G
|
Rasef
|
RAS and EF hand domain containing
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA panobinostat results in increased expression of RASEF mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:92,595,148...92,665,526
Ensembl chr 5:92,595,148...92,666,117
|
|
G
|
Rasgrp2
|
RAS guanyl releasing protein 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:213,135,034...213,152,246
Ensembl chr 1:213,136,015...213,151,884
|
|
G
|
Rassf1
|
Ras association domain family member 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of RASSF1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:117,103,665...117,114,805
Ensembl chr 8:117,103,362...117,114,805
|
|
G
|
Rassf10
|
Ras association domain family member 10
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA panobinostat results in decreased expression of RASSF10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:167,058,277...167,063,591
Ensembl chr 1:176,492,839...176,495,758
|
|
G
|
Rassf3
|
Ras association domain family member 3
|
increases expression
|
ISO
|
panobinostat results in increased expression of RASSF3 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 7:58,821,360...58,886,020
Ensembl chr 7:58,821,360...58,886,020
|
|
G
|
Rassf6
|
Ras association domain family member 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:17,433,328...17,473,565
Ensembl chr14:17,717,567...17,760,378
|
|
G
|
Rax
|
retina and anterior neural fold homeobox
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA panobinostat results in decreased expression of RAX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:61,733,322...61,737,444
Ensembl chr18:61,733,322...61,737,444
|
|
G
|
Rbfox1
|
RNA binding fox-1 homolog 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA panobinostat results in increased expression of RBFOX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:8,658,809...10,754,648
Ensembl chr10:8,658,809...10,754,706
|
|
G
|
Rbfox3
|
RNA binding fox-1 homolog 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA panobinostat results in decreased expression of RBFOX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:104,218,940...104,655,863
Ensembl chr10:104,218,940...104,551,945
|
|
G
|
Rbm22
|
RNA binding motif protein 22
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of RBM22 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr18:56,283,807...56,294,615
Ensembl chr18:56,283,770...56,295,073
|
|
G
|
Rbm24
|
RNA binding motif protein 24
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA panobinostat results in decreased expression of RBM24 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:18,481,893...18,494,440
Ensembl chr17:18,481,900...18,494,604
|
|
G
|
Rbm43
|
RNA binding motif protein 43
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA panobinostat results in increased expression of RBM43 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:56,802,384...56,821,371
Ensembl chr 3:56,803,593...56,811,350
|
|
G
|
Rbm47
|
RNA binding motif protein 47
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:42,407,226...42,545,304
Ensembl chr14:42,466,335...42,543,163
|
|
G
|
Rbms3
|
RNA binding motif, single stranded interacting protein 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:125,183,315...126,503,586
|
|
G
|
Rbp1
|
retinol binding protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA panobinostat results in increased expression of RBP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:107,887,417...107,983,847
|
|
G
|
Rbpms2
|
RNA binding protein, mRNA processing factor 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA panobinostat results in increased expression of RBPMS2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:75,048,159...75,079,393
Ensembl chr 8:75,048,263...75,079,396
|
|
G
|
Rcan1
|
regulator of calcineurin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA panobinostat results in increased expression of RCAN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:45,108,123...45,188,065
Ensembl chr11:45,108,124...45,118,236
|
|
G
|
Rdm1
|
RAD52 motif containing 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:86,562,871...86,573,034
Ensembl chr10:87,039,940...87,073,273
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
panobinostat results in increased activity of and results in decreased acetylation of RELA protein; resveratrol inhibits the reaction [panobinostat results in increased activity of and results in decreased acetylation of RELA protein]
|
CTD |
PMID:22923501 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Reln
|
reelin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA panobinostat results in increased expression of RELN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:13,628,440...14,055,201
Ensembl chr 4:13,628,399...14,055,162
|
|
G
|
Rest
|
RE1-silencing transcription factor
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA panobinostat results in increased expression of REST mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:31,213,415...31,233,451
Ensembl chr14:31,213,415...31,248,662
|
|
G
|
Rftn2
|
raftlin family member 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA panobinostat results in increased expression of RFTN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:64,146,062...64,202,342
Ensembl chr 9:64,124,865...64,215,186
|
|
G
|
Rfx3
|
regulatory factor X3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:234,863,462...235,122,989
Ensembl chr 1:234,863,462...235,122,536
|
|
G
|
Rfx4
|
regulatory factor X4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA panobinostat results in increased expression of RFX4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:20,740,760...20,903,355
Ensembl chr 7:20,741,079...20,902,851
|
|
G
|
RGD1359108
|
similar to RIKEN cDNA 3110043O21
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of C9ORF72 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:54,562,570...54,587,649
Ensembl chr 5:54,562,570...54,587,637
|
|
G
|
Rgma
|
repulsive guidance molecule BMP co-receptor a
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA panobinostat results in decreased expression of RGMA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:136,538,782...136,582,763
Ensembl chr 1:136,538,759...136,582,763
|
|
G
|
Rgs5
|
regulator of G-protein signaling 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA panobinostat results in increased expression of RGS5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:84,381,077...84,417,875
Ensembl chr13:84,380,910...84,421,352
|
|
G
|
Rhob
|
ras homolog family member B
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of RHOB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772
|
|
G
|
Rhobtb3
|
Rho-related BTB domain containing 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA panobinostat results in increased expression of RHOBTB3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:7,094,972...7,201,507
Ensembl chr 2:7,095,253...7,150,906
|
|
G
|
Rhoh
|
ras homolog family member H
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:42,694,860...42,725,690
Ensembl chr14:42,693,413...42,749,967
|
|
G
|
Rims1
|
regulating synaptic membrane exocytosis 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA panobinostat results in increased expression of RIMS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:32,193,352...32,692,998
Ensembl chr 9:32,193,352...32,692,772
|
|
G
|
Ripk4
|
receptor-interacting serine-threonine kinase 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA panobinostat results in increased expression of RIPK4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:50,591,926...50,614,169
Ensembl chr11:50,591,936...50,614,169
|
|
G
|
Rnd3
|
Rho family GTPase 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA panobinostat results in increased expression of RND3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:55,980,355...55,998,536
|
|
G
|
Rnf144b
|
ring finger protein 144B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA panobinostat results in increased expression of RNF144B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037
|
|
G
|
Rnf150
|
ring finger protein 150
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA panobinostat results in increased expression of RNF150 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:25,006,978...25,229,273
Ensembl chr19:41,912,276...42,133,217
|
|
G
|
Rnf182
|
ring finger protein 182
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA panobinostat results in decreased expression of RNF182 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:21,026,110...21,081,760
Ensembl chr17:21,232,084...21,299,723
|
|
G
|
Rnf217
|
ring finger protein 217
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA panobinostat results in increased expression of RNF217 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:27,835,148...27,928,044
|
|
G
|
Rnf24
|
ring finger protein 24
|
increases expression
|
ISO
|
Panobinostat results in increased expression of RNF24 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 3:138,973,492...138,987,354
Ensembl chr 3:138,973,492...139,028,177
|
|
G
|
Rnf43
|
ring finger protein 43
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA panobinostat results in increased expression of RNF43 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:72,958,744...73,034,540
Ensembl chr10:72,961,641...73,034,551
|
|
G
|
Robo2
|
roundabout guidance receptor 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr11:26,015,919...27,583,750
Ensembl chr11:26,015,919...26,876,185
|
|
G
|
Ror1
|
receptor tyrosine kinase-like orphan receptor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA panobinostat results in increased expression of ROR1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:119,859,744...120,203,573
Ensembl chr 5:119,859,970...120,205,801
|
|
G
|
Rpl31
|
ribosomal protein L31
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA panobinostat results in decreased expression of RPL31 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:49,142,955...49,147,155
|
|
G
|
Rpp25
|
ribonuclease P and MRP subunit p25
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA panobinostat results in increased expression of RPP25 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:66,803,262...66,804,642
Ensembl chr 8:66,803,212...66,810,550
|
|
G
|
Rprm
|
reprimo, TP53 dependent G2 arrest mediator homolog
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA panobinostat results in increased expression of RPRM mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:58,948,618...58,950,035
Ensembl chr 3:58,799,866...58,950,542
|
|
G
|
Rprml
|
reprimo-like
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA panobinostat results in increased expression of RPRML mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:89,060,280...89,061,284
Ensembl chr10:89,059,522...89,063,831
|
|
G
|
Rps24
|
ribosomal protein S24
|
increases expression
|
ISO
|
panobinostat results in increased expression of RPS24 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr16:95,429...101,146
Ensembl chr16:96,484...101,144
|
|
G
|
Rps6ka6
|
ribosomal protein S6 kinase A6
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA panobinostat results in decreased expression of RPS6KA6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:80,537,723...80,638,910
Ensembl chr X:80,537,723...80,692,148
|
|
G
|
Rragd
|
Ras-related GTP binding D
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA panobinostat results in decreased expression of RRAGD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:52,170,234...52,205,700
Ensembl chr 5:52,169,783...52,209,000
|
|
G
|
Rreb1
|
ras responsive element binding protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA panobinostat results in increased expression of RREB1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:27,082,217...27,208,061
Ensembl chr17:27,082,227...27,208,061
|
|
G
|
Rspo2
|
R-spondin 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA panobinostat results in decreased expression of RSPO2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:75,987,217...76,123,984
Ensembl chr 7:75,987,817...76,123,654
|
|
G
|
Rspo3
|
R-spondin 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA panobinostat results in increased expression of RSPO3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:30,112,529...30,197,267
Ensembl chr 1:30,112,114...30,197,938
|
|
G
|
RT1-Bb
|
RT1 class II, locus Bb
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118
|
|
G
|
RT1-DMa
|
RT1 class II, locus DMa
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA panobinostat results in increased expression of HLA-DMA mRNA
|
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335
|
|
G
|
RT1-DMb
|
RT1 class II, locus DMb
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of HLA-DMB mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246
|
|
G
|
RT1-Ha
|
RT1 class II, locus Ha
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of HLA-DPA1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141
|
|
G
|
Rtn1
|
reticulon 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA panobinostat results in decreased expression of RTN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:96,499,137...96,719,340
Ensembl chr 6:96,499,134...96,719,340
|
|
G
|
Rtp1
|
receptor (chemosensory) transporter protein 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr11:90,927,633...90,930,149
Ensembl chr11:90,927,633...90,930,149
|
|
G
|
Runx1t1
|
RUNX1 partner transcriptional co-repressor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA panobinostat results in increased expression of RUNX1T1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:31,984,855...32,132,855
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Runx3
|
RUNX family transcription factor 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA panobinostat results in increased expression of RUNX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835
|
|
G
|
Ryr3
|
ryanodine receptor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA panobinostat results in decreased expression of RYR3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677
|
|
G
|
S100a10
|
S100 calcium binding protein A10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA panobinostat results in increased expression of S100A10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103
|
|
G
|
S100a11
|
S100 calcium binding protein A11
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA panobinostat results in increased expression of S100A11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541
|
|
G
|
S100a4
|
S100 calcium-binding protein A4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA panobinostat results in increased expression of S100A4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837
|
|
G
|
S100a6
|
S100 calcium binding protein A6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA panobinostat results in increased expression of S100A6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762
|
|
G
|
S100b
|
S100 calcium binding protein B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA panobinostat results in increased expression of S100B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081
|
|
G
|
S1pr3
|
sphingosine-1-phosphate receptor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA panobinostat results in decreased expression of S1PR3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:13,932,773...13,946,213
Ensembl chr17:13,928,444...13,947,197
|
|
G
|
S1pr5
|
sphingosine-1-phosphate receptor 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA panobinostat results in increased expression of S1PR5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:28,062,841...28,068,013
Ensembl chr 8:28,061,752...28,068,389
|
|
G
|
Sall2
|
spalt-like transcription factor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA panobinostat results in decreased expression of SALL2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:27,494,831...27,512,402
Ensembl chr15:27,494,589...27,512,402
|
|
G
|
Sall3
|
spalt-like transcription factor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA panobinostat results in decreased expression of SALL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:76,680,997...76,700,905
Ensembl chr18:76,681,005...76,700,905
|
|
G
|
Sat1
|
spermidine/spermine N1-acetyl transferase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA panobinostat results in increased expression of SAT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374
|
|
G
|
Sbf2
|
SET binding factor 2
|
increases expression
|
ISO
|
panobinostat results in increased expression of SBF2 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 1:173,787,638...174,154,589
Ensembl chr 1:173,788,187...174,154,522
|
|
G
|
Sccpdh
|
saccharopine dehydrogenase (putative)
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of SCCPDH mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:93,932,086...93,953,840
Ensembl chr13:93,912,395...93,954,192
|
|
G
|
Scg3
|
secretogranin III
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA panobinostat results in increased expression of SCG3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,280,253...85,322,484
Ensembl chr 8:85,280,253...85,361,874
|
|
G
|
Scgb3a2
|
secretoglobin, family 3A, member 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA panobinostat results in increased expression of SCGB3A2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:36,183,745...36,186,667
Ensembl chr18:36,183,698...36,186,742
|
|
G
|
Scgn
|
secretagogin, EF-hand calcium binding protein
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr17:41,534,558...41,576,525
Ensembl chr17:41,534,497...41,576,522
|
|
G
|
Scml1
|
Scm polycomb group protein like 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA panobinostat results in increased expression of SCML1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:36,526,068...36,543,336
Ensembl chr X:36,526,068...36,544,450
|
|
G
|
Scn2b
|
sodium voltage-gated channel beta subunit 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SCN2B mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:54,322,383...54,334,519
Ensembl chr 8:54,322,383...54,334,519
|
|
G
|
Scn4b
|
sodium voltage-gated channel beta subunit 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA panobinostat results in increased expression of SCN4B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:54,343,873...54,359,046
Ensembl chr 8:54,334,548...54,359,047
|
|
G
|
Scn7a
|
sodium voltage-gated channel alpha subunit 7
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA panobinostat results in decreased expression of SCN7A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:71,743,873...71,846,454
Ensembl chr 3:71,743,873...71,846,284
|
|
G
|
Scnn1a
|
sodium channel epithelial 1 subunit alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA panobinostat results in increased expression of SCNN1A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405
|
|
G
|
Scnn1g
|
sodium channel epithelial 1 subunit gamma
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA panobinostat results in increased expression of SCNN1G mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097
|
|
G
|
Scrg1
|
stimulator of chondrogenesis 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA panobinostat results in increased expression of SCRG1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:32,760,028...32,788,299
Ensembl chr16:37,770,739...37,799,010
|
|
G
|
Scube2
|
signal peptide, CUB domain and EGF like domain containing 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA panobinostat results in decreased expression of SCUBE2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:173,264,862...173,341,323
Ensembl chr 1:173,264,865...173,334,372
|
|
G
|
Sdc4
|
syndecan 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA panobinostat results in increased expression of SDC4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670
|
|
G
|
Sec24d
|
SEC24 homolog D, COPII coat complex component
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA panobinostat results in increased expression of SEC24D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:214,103,138...214,211,155
Ensembl chr 2:214,103,190...214,211,144
|
|
G
|
Selenoi
|
selenoprotein I
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA panobinostat results in increased expression of SELENOI mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:26,073,127...26,111,326
Ensembl chr 6:31,792,973...31,831,523
|
|
G
|
Selenop
|
selenoprotein P
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA panobinostat results in increased expression of SELENOP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019
|
|
G
|
Sema3c
|
semaphorin 3C
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA panobinostat results in increased expression of SEMA3C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740
|
|
G
|
Sema3e
|
semaphorin 3E
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA panobinostat results in increased expression of SEMA3E mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:21,252,686...21,510,449
Ensembl chr 4:21,210,734...21,510,374
|
|
G
|
Sema5a
|
semaphorin 5A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA panobinostat results in decreased expression of SEMA5A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:85,020,724...85,451,938
Ensembl chr 2:85,020,724...85,451,938
|
|
G
|
Sema6d
|
semaphorin 6D
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA panobinostat results in decreased expression of SEMA6D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:132,337,343...132,394,584
|
|
G
|
Senp6
|
SUMO specific peptidase 6
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of SENP6 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of SENP6 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 8:89,868,115...89,951,803
Ensembl chr 8:89,868,867...89,948,062
|
|
G
|
Septin6
|
septin 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA Panobinostat results in increased expression of SEPTIN6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:121,018,951...121,157,677
Ensembl chr X:121,018,944...121,095,792
|
|
G
|
Serpinb9
|
serpin family B member 9
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA panobinostat results in increased expression of SERPINB9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974
|
|
G
|
Serpinf1
|
serpin family F member 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA panobinostat results in decreased expression of SERPINF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,748,506...60,760,898
|
|
G
|
Sestd1
|
SEC14 and spectrin domain containing 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA panobinostat results in decreased expression of SESTD1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:82,530,796...82,627,960
Ensembl chr 3:82,537,092...82,588,078
|
|
G
|
Sez6
|
seizure related 6 homolog
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA panobinostat results in increased expression of SEZ6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:63,317,065...63,366,733
Ensembl chr10:63,316,953...63,366,723
|
|
G
|
Sfmbt1
|
Scm-like with four mbt domains 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA panobinostat results in decreased expression of SFMBT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:5,889,046...6,009,860
Ensembl chr16:5,897,187...6,011,934
|
|
G
|
Sfmbt2
|
Scm-like with four mbt domains 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA panobinostat results in increased expression of SFMBT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:72,844,037...73,038,599
Ensembl chr17:72,845,708...73,032,172
|
|
G
|
Sfn
|
stratifin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA panobinostat results in increased expression of SFN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995
|
|
G
|
Sfrp1
|
secreted frizzled-related protein 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA panobinostat results in decreased expression of SFRP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:75,278,325...75,316,736
Ensembl chr16:75,278,325...75,316,736
|
|
G
|
Sfrp2
|
secreted frizzled-related protein 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA panobinostat results in decreased expression of SFRP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079
|
|
G
|
Sgk3
|
serum/glucocorticoid regulated kinase family, member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA panobinostat results in increased expression of SGK3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:14,128,628...14,255,099
Ensembl chr 5:14,126,257...14,198,331
|
|
G
|
Sgpp1
|
sphingosine-1-phosphate phosphatase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA panobinostat results in increased expression of SGPP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:100,161,024...100,182,214
Ensembl chr 6:100,161,024...100,182,259
|
|
G
|
Sgpp2
|
sphingosine-1-phosphate phosphatase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA panobinostat results in increased expression of SGPP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:87,211,155...87,331,787
Ensembl chr 9:87,211,717...87,333,132
|
|
G
|
Sh3kbp1
|
SH3 domain-containing kinase-binding protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA panobinostat results in increased expression of SH3KBP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:38,686,530...39,031,658
Ensembl chr X:38,686,530...39,031,393
|
|
G
|
Shb
|
SH2 domain containing adaptor protein B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA panobinostat results in increased expression of SHB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:64,473,694...64,581,072
Ensembl chr 5:64,473,694...64,581,072
|
|
G
|
Shc3
|
SHC adaptor protein 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr17:13,803,980...13,924,433
Ensembl chr17:13,803,781...13,924,433
|
|
G
|
Shisa2
|
shisa family member 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:37,982,913...37,987,211
Ensembl chr15:37,982,169...37,988,535
|
|
G
|
Shisa6
|
shisa family member 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:51,396,806...51,691,156
Ensembl chr10:51,396,806...51,691,156
|
|
G
|
Sik1
|
salt-inducible kinase 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,105...9,958,698
|
|
G
|
Six1
|
SIX homeobox 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA panobinostat results in increased expression of SIX1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:97,482,617...97,487,853
Ensembl chr 6:97,482,617...97,487,853
|
|
G
|
Six3
|
SIX homeobox 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA panobinostat results in decreased expression of SIX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:14,791,937...14,796,365
Ensembl chr 6:14,789,354...14,804,175
|
|
G
|
Six6
|
SIX homeobox 6
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA panobinostat results in decreased expression of SIX6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:97,357,883...97,375,415
Ensembl chr 6:97,370,435...97,375,415
|
|
G
|
Six6os1
|
Six6 opposite strand transcript 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA panobinostat results in decreased expression of C14ORF39 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:97,314,829...97,351,069
Ensembl chr 6:97,314,712...97,351,171
|
|
G
|
Skap2
|
src kinase associated phosphoprotein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA panobinostat results in increased expression of SKAP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:82,281,221...82,431,664
Ensembl chr 4:82,263,709...82,432,886
|
|
G
|
Slc16a1
|
solute carrier family 16 member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA panobinostat results in increased expression of SLC16A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977
|
|
G
|
Slc16a14
|
solute carrier family 16, member 14
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA panobinostat results in decreased expression of SLC16A14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:93,558,144...93,585,396
Ensembl chr 9:93,558,144...93,585,396
|
|
G
|
Slc16a4
|
solute carrier family 16, member 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA panobinostat results in increased expression of SLC16A4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:197,593,738...197,621,569
Ensembl chr 2:197,599,295...197,621,562
|
|
G
|
Slc17a5
|
solute carrier family 17 member 5
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SLC17A5 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:88,274,497...88,309,734
Ensembl chr 8:88,274,721...88,309,664
|
|
G
|
Slc18b1
|
solute carrier family 18 member B1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA panobinostat results in increased expression of SLC18B1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:23,447,462...23,490,043
Ensembl chr 1:23,447,462...23,489,962
|
|
G
|
Slc19a3
|
solute carrier family 19 member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA panobinostat results in increased expression of SLC19A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:91,724,718...91,754,991
|
|
G
|
Slc1a1
|
solute carrier family 1 member 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SLC1A1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469
|
|
G
|
Slc1a3
|
solute carrier family 1 member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA panobinostat results in increased expression of SLC1A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:59,482,707...59,557,808
Ensembl chr 2:59,482,709...59,557,808
|
|
G
|
Slc24a3
|
solute carrier family 24 member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA panobinostat results in increased expression of SLC24A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:153,005,418...153,504,497
Ensembl chr 3:153,004,987...153,504,497
|
|
G
|
Slc25a12
|
solute carrier family 25 member 12
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA panobinostat results in increased expression of SLC25A12 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:76,504,868...76,599,536
Ensembl chr 3:76,504,868...76,599,536
|
|
G
|
Slc25a16
|
solute carrier family 25 member 16
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA panobinostat results in increased expression of SLC25A16 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:25,659,847...25,717,080
Ensembl chr20:25,660,339...25,689,285 Ensembl chr20:25,660,339...25,689,285
|
|
G
|
Slc25a25
|
solute carrier family 25 member 25
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SLC25A25 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 3:36,106,448...36,139,812
Ensembl chr 3:36,106,449...36,140,011
|
|
G
|
Slc25a53
|
solute carrier family 25, member 53
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA panobinostat results in decreased expression of SLC25A53 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:105,099,191...105,111,936
Ensembl chr X:105,099,112...105,113,009
|
|
G
|
Slc27a2
|
solute carrier family 27 member 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581
|
|
G
|
Slc2a3
|
solute carrier family 2 member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA panobinostat results in increased expression of SLC2A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186
|
|
G
|
Slc30a4
|
solute carrier family 30 member 4
|
increases expression
|
ISO
|
panobinostat results in increased expression of SLC30A4 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 3:130,206,852...130,228,888
Ensembl chr 3:130,206,852...130,228,888
|
|
G
|
Slc35d3
|
solute carrier family 35, member D3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:16,389,308...16,392,780
Ensembl chr 1:16,389,308...16,392,780
|
|
G
|
Slc35f2
|
solute carrier family 35, member F2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA panobinostat results in increased expression of SLC35F2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:63,055,503...63,099,791
Ensembl chr 8:63,056,105...63,099,789
|
|
G
|
Slc35g2
|
solute carrier family 35, member G2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:109,964,589...109,992,347
Ensembl chr 8:109,964,378...109,992,412
|
|
G
|
Slc38a6
|
solute carrier family 38, member 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 6:97,723,526...97,814,394
Ensembl chr 6:97,723,471...97,785,791
|
|
G
|
Slc39a6
|
solute carrier family 39 member 6
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of SLC39A6 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr18:16,139,621...16,160,163
Ensembl chr18:16,135,008...16,160,163
|
|
G
|
Slc39a7
|
solute carrier family 39 member 7
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SLC39A7 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr20:4,824,967...4,828,431
Ensembl chr20:4,824,688...4,828,430
|
|
G
|
Slc39a8
|
solute carrier family 39 member 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA panobinostat results in increased expression of SLC39A8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667
|
|
G
|
Slc40a1
|
solute carrier family 40 member 1
|
multiple interactions increases expression
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA panobinostat results in increased expression of SLC40A1 mRNA
|
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460
|
|
G
|
Slc43a1
|
solute carrier family 43 member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA panobinostat results in increased expression of SLC43A1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:90,327,250...90,353,438
Ensembl chr 3:90,327,149...90,353,438
|
|
G
|
Slc52a3
|
solute carrier family 52 member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA panobinostat results in increased expression of SLC52A3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:160,959,233...160,976,170
Ensembl chr 3:160,965,302...160,974,692
|
|
G
|
Slc6a8
|
solute carrier family 6 member 8
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA panobinostat results in decreased expression of SLC6A8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:156,536,017...156,545,321
Ensembl chr X:156,536,017...156,545,321
|
|
G
|
Slc7a10
|
solute carrier family 7 member 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA panobinostat results in increased expression of SLC7A10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:96,966,030...96,982,020
Ensembl chr 1:96,966,076...96,982,018
|
|
G
|
Slc7a11
|
solute carrier family 7 member 11
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA panobinostat results in increased expression of SLC7A11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
G
|
Slc7a5
|
solute carrier family 7 member 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA panobinostat results in increased expression of SLC7A5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412
|
|
G
|
Slc9b2
|
solute carrier family 9 member B2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA panobinostat results in decreased expression of SLC9B2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:226,400,358...226,435,039
Ensembl chr 2:226,410,263...226,435,030
|
|
G
|
Slco4c1
|
solute carrier organic anion transporter family, member 4C1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA panobinostat results in increased expression of SLCO4C1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462
|
|
G
|
Slfn5
|
schlafen family member 5
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:68,378,440...68,392,515
Ensembl chr10:68,378,449...68,392,544
|
|
G
|
Slit1
|
slit guidance ligand 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA panobinostat results in increased expression of SLIT1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:250,358,917...250,507,476
Ensembl chr 1:250,358,919...250,507,476
|
|
G
|
Slit2
|
slit guidance ligand 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA panobinostat results in increased expression of SLIT2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:66,829,661...67,168,517
Ensembl chr14:66,829,661...67,167,146
|
|
G
|
Slit3
|
slit guidance ligand 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA panobinostat results in increased expression of SLIT3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:20,075,929...20,660,704
Ensembl chr10:20,076,021...20,660,704
|
|
G
|
Slitrk6
|
SLIT and NTRK-like family, member 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA panobinostat results in increased expression of SLITRK6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:93,977,812...93,984,431
Ensembl chr15:93,969,038...93,984,526
|
|
G
|
Smad2
|
SMAD family member 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA panobinostat results in decreased expression of SMAD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
|
|
G
|
Smarca2
|
SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA panobinostat results in increased expression of SMARCA2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:233,617,277...233,784,908
Ensembl chr 1:233,617,366...233,784,869
|
|
G
|
Smim14
|
small integral membrane protein 14
|
increases expression
|
ISO
|
Panobinostat results in increased expression of SMIM14 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr14:42,783,361...42,829,762
Ensembl chr14:43,136,867...43,183,416
|
|
G
|
Smoc1
|
SPARC related modular calcium binding 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA panobinostat results in decreased expression of SMOC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:106,432,603...106,593,956
|
|
G
|
Smoc2
|
SPARC related modular calcium binding 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:63,935,647...64,064,955
|
|
G
|
Smpdl3a
|
sphingomyelin phosphodiesterase, acid-like 3A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr20:37,679,004...37,701,979
Ensembl chr20:37,678,964...37,704,260
|
|
G
|
Smyd2
|
SET and MYND domain containing 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA panobinostat results in increased expression of SMYD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:103,956,470...103,997,774
Ensembl chr13:103,956,473...103,997,774
|
|
G
|
Snai2
|
snail family transcriptional repressor 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA panobinostat results in increased expression of SNAI2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349
|
|
G
|
Snap25
|
synaptosome associated protein 25
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA panobinostat results in increased expression of SNAP25 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448
|
|
G
|
Snrk
|
SNF related kinase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SNRK mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:130,657,204...130,711,461
Ensembl chr 8:130,657,266...130,711,457
|
|
G
|
Snx25
|
sorting nexin 25
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA panobinostat results in decreased expression of SNX25 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:52,867,102...52,971,028
Ensembl chr16:52,858,532...52,971,008
|
|
G
|
Socs1
|
suppressor of cytokine signaling 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA panobinostat results in increased expression of SOCS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847
|
|
G
|
Socs2
|
suppressor of cytokine signaling 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA panobinostat results in increased expression of SOCS2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA panobinostat results in decreased expression of SOCS3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Sorcs2
|
sortilin-related VPS10 domain containing receptor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA panobinostat results in decreased expression of SORCS2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:78,592,290...78,960,582
Ensembl chr14:78,596,087...78,960,582
|
|
G
|
Sord
|
sorbitol dehydrogenase
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA panobinostat results in decreased expression of SORD mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
|
|
G
|
Sost
|
sclerostin
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:87,412,722...87,415,766
Ensembl chr10:87,411,721...87,415,766
|
|
G
|
Sox10
|
SRY-box transcription factor 10
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA panobinostat results in increased expression of SOX10 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:112,605,721...112,615,097
Ensembl chr 7:112,605,721...112,615,990
|
|
G
|
Sox11
|
SRY-box transcription factor 11
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA panobinostat results in decreased expression of SOX11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA panobinostat results in decreased expression of SOX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350
|
|
G
|
Sox3
|
SRY-box transcription factor 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA panobinostat results in decreased expression of SOX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:144,344,892...144,346,971
Ensembl chr X:144,344,892...144,346,987
|
|
G
|
Sox8
|
SRY-box transcription factor 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA panobinostat results in increased expression of SOX8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:15,089,357...15,094,345
Ensembl chr10:15,089,357...15,094,345
|
|
G
|
Sox9
|
SRY-box transcription factor 9
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA panobinostat results in increased expression of SOX9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250
|
|
G
|
Sp5
|
Sp5 transcription factor
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA panobinostat results in increased expression of SP5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:75,682,677...75,685,479
Ensembl chr 3:75,682,677...75,685,479
|
|
G
|
Sp6
|
Sp6 transcription factor
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA panobinostat results in increased expression of SP6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:82,501,957...82,506,138
Ensembl chr10:82,501,726...82,508,887
|
|
G
|
Sp8
|
Sp8 transcription factor
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of SP8 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 6:145,959,219...145,961,824
Ensembl chr 6:145,959,097...145,964,845
|
|
G
|
Spag1
|
sperm associated antigen 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:69,246,301...69,306,483
Ensembl chr 7:69,246,582...69,306,482
|
|
G
|
Spag9
|
sperm associated antigen 9
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:79,440,311...79,574,709
Ensembl chr10:79,440,377...79,575,258
|
|
G
|
Sphk1
|
sphingosine kinase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA panobinostat results in increased expression of SPHK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082
|
|
G
|
Spink1
|
serine peptidase inhibitor, Kazal type 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA panobinostat results in increased expression of SPINK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545
|
|
G
|
Spink2
|
serine peptidase inhibitor, Kazal type 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA panobinostat results in increased expression of SPINK2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:31,321,976...31,328,622
Ensembl chr14:31,322,010...31,328,622
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA panobinostat results in increased expression of SPP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
G
|
Spry1
|
sprouty RTK signaling antagonist 1
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of SPRY1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 2:122,484,995...122,490,008
Ensembl chr 2:122,484,355...122,492,956
|
|
G
|
Spsb4
|
splA/ryanodine receptor domain and SOCS box containing 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA panobinostat results in increased expression of SPSB4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:106,416,039...106,489,271
Ensembl chr 8:106,416,040...106,489,271
|
|
G
|
Sqor
|
sulfide quinone oxidoreductase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA panobinostat results in increased expression of SQOR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:130,294,783...130,341,655
Ensembl chr 3:130,292,814...130,340,799
|
|
G
|
Srcin1
|
SRC kinase signaling inhibitor 1
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA panobinostat results in decreased expression of SRCIN1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:82,999,295...83,066,359
Ensembl chr10:82,991,033...83,067,419
|
|
G
|
Ssbp2
|
single-stranded DNA binding protein 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA panobinostat results in decreased expression of SSBP2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:24,385,494...24,673,768
Ensembl chr 2:24,385,687...24,673,768
|
|
G
|
Sst
|
somatostatin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA panobinostat results in increased expression of SST mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:90,461,546...90,462,823
Ensembl chr11:90,461,546...90,462,823
|
|
G
|
St14
|
ST14 transmembrane serine protease matriptase
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:37,798,995...37,855,652
|
|
G
|
St3gal1
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA panobinostat results in increased expression of ST3GAL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242
|
|
G
|
St3gal5
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 5
|
increases expression
|
ISO
|
Panobinostat results in increased expression of ST3GAL5 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 4:105,692,840...105,750,774
Ensembl chr 4:105,692,840...105,750,775
|
|
G
|
St6galnac2
|
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:102,409,048...102,427,299
Ensembl chr10:102,409,048...102,427,137
|
|
G
|
St6galnac5
|
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA panobinostat results in decreased expression of ST6GALNAC5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:244,398,604...244,571,100
Ensembl chr 2:244,402,589...244,571,097
|
|
G
|
St8sia2
|
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ST8SIA2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA2 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 1:137,172,354...137,247,796
Ensembl chr 1:137,172,354...137,247,792
|
|
G
|
St8sia3
|
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of ST8SIA3 mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA3 mRNA] panobinostat affects the expression of ST8SIA3 mRNA
|
CTD |
PMID:26733615 |
|
NCBI chr18:60,024,555...60,031,050
Ensembl chr18:60,024,236...60,032,473
|
|
G
|
Stam2
|
signal transducing adaptor molecule 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:57,597,557...57,643,915
Ensembl chr 3:57,597,559...57,643,915
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions increases acetylation
|
ISO
|
Panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; Panobinostat promotes the reaction [Resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; Panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]] Panobinostat results in increased acetylation of STAT3 protein
|
CTD |
PMID:23681230 PMID:26775640 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stat6
|
signal transducer and activator of transcription 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA panobinostat results in increased expression of STAT6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:65,365,306...65,383,795
|
|
G
|
Stc1
|
stanniocalcin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA panobinostat results in increased expression of STC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082
|
|
G
|
Steap1
|
STEAP family member 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA
|
CTD |
PMID:21791302 PMID:27188386 |
|
NCBI chr 4:29,231,809...29,242,317
Ensembl chr 4:29,231,753...29,242,317
|
|
G
|
Steap3
|
STEAP3 metalloreductase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA panobinostat results in increased expression of STEAP3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:33,904,710...33,950,100
Ensembl chr13:33,904,710...33,950,080
|
|
G
|
Stimate
|
STIM activating enhancer
|
increases expression
|
ISO
|
Panobinostat results in increased expression of STIMATE-MUSTN1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr16:6,019,788...6,077,272
Ensembl chr16:6,019,793...6,079,110
|
|
G
|
Stk32a
|
serine/threonine kinase 32A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA panobinostat results in decreased expression of STK32A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:35,509,791...35,620,421
Ensembl chr18:35,509,982...35,628,985
|
|
G
|
Stmn2
|
stathmin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA panobinostat results in increased expression of STMN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335
|
|
G
|
Stom
|
stomatin
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:39,042,503...39,064,818
Ensembl chr 3:39,042,503...39,064,818
|
|
G
|
Ston1
|
stonin 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of STON1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 6:11,596,726...11,646,098
Ensembl chr 6:11,572,905...11,615,635
|
|
G
|
Stox1
|
storkhead box 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr20:31,140,993...31,209,126
Ensembl chr20:31,140,993...31,208,877
|
|
G
|
Stra6
|
signaling receptor and transporter of retinol STRA6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA panobinostat results in increased expression of STRA6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:67,444,757...67,464,719
Ensembl chr 8:67,444,742...67,464,720
|
|
G
|
Styk1
|
serine/threonine/tyrosine kinase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA panobinostat results in increased expression of STYK1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:165,047,613...165,097,890
Ensembl chr 4:166,779,040...166,827,738
|
|
G
|
Sulf2
|
sulfatase 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of SULF2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651
|
|
G
|
Sult1a1
|
sulfotransferase family 1A member 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131
|
|
G
|
Sult1c2a
|
sulfotransferase family 1C member 2A
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of SULT1C2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132
|
|
G
|
Susd2
|
sushi domain containing 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA panobinostat results in increased expression of SUSD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:13,016,960...13,024,264
Ensembl chr20:13,016,907...13,024,264
|
|
G
|
Susd3
|
sushi domain containing 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA panobinostat results in increased expression of SUSD3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:15,607,259...15,623,322
Ensembl chr17:15,606,906...15,624,262
|
|
G
|
Sv2c
|
synaptic vesicle glycoprotein 2c
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA panobinostat results in increased expression of SV2C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:28,967,631...29,163,168
Ensembl chr 2:28,964,582...29,163,168
|
|
G
|
Syk
|
spleen associated tyrosine kinase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA panobinostat results in increased expression of SYK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278
|
|
G
|
Syncrip
|
synaptotagmin binding, cytoplasmic RNA interacting protein
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:98,282,358...98,315,412
Ensembl chr 8:98,282,358...98,315,386
|
|
G
|
Syne1
|
spectrin repeat containing nuclear envelope protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA panobinostat results in increased expression of SYNE1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721
|
|
G
|
Syne3
|
spectrin repeat containing, nuclear envelope family member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA panobinostat results in increased expression of SYNE3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:129,637,644...129,729,542
Ensembl chr 6:129,641,123...129,729,509
|
|
G
|
Syngr1
|
synaptogyrin 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA panobinostat results in increased expression of SYNGR1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:113,516,246...113,542,918
Ensembl chr 7:113,516,265...113,542,917
|
|
G
|
Synpr
|
synaptoporin
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA panobinostat results in increased expression of SYNPR mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:14,003,861...14,330,808
Ensembl chr15:14,004,715...14,330,848
|
|
G
|
Syt11
|
synaptotagmin 11
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA panobinostat results in decreased expression of SYT11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:176,503,845...176,530,354
Ensembl chr 2:176,503,845...176,529,775
|
|
G
|
Syt4
|
synaptotagmin 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA panobinostat results in increased expression of SYT4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:23,311,454...23,320,863
Ensembl chr18:23,312,859...23,320,815
|
|
G
|
Syt7
|
synaptotagmin 7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of SYT7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:216,456,148...216,518,718
Ensembl chr 1:216,456,259...216,518,718
|
|
G
|
Sytl2
|
synaptotagmin-like 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 1:153,685,403...153,791,758
Ensembl chr 1:153,665,327...153,791,756
|
|
G
|
Sytl4
|
synaptotagmin-like 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:101,428,785...101,479,207
Ensembl chr X:101,428,785...101,479,151
|
|
G
|
Tac1
|
tachykinin, precursor 1
|
increases expression
|
ISO
|
panobinostat results in increased expression of TAC1 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
|
|
G
|
Tacc1
|
transforming, acidic coiled-coil containing protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA panobinostat results in increased expression of TACC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:66,812,232...66,895,736
Ensembl chr16:73,514,889...73,598,394
|
|
G
|
Tacstd2
|
tumor-associated calcium signal transducer 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA panobinostat results in increased expression of TACSTD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:98,033,251...98,039,323
|
|
G
|
Tagln2
|
transgelin 2
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of TAGLN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:87,499,350...87,506,328
Ensembl chr13:87,499,394...87,506,330
|
|
G
|
Tanc1
|
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA panobinostat results in increased expression of TANC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:64,508,037...64,741,826
Ensembl chr 3:64,508,085...64,741,825
|
|
G
|
Tars1
|
threonyl-tRNA synthetase 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA Panobinostat results in increased expression of TARS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:62,087,763...62,114,802
|
|
G
|
Tbc1d16
|
TBC1 domain family, member 16
|
increases expression
|
ISO
|
Panobinostat results in increased expression of TBC1D16 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr10:104,899,507...104,985,233
Ensembl chr10:104,899,507...104,985,216
|
|
G
|
Tbc1d30
|
TBC1 domain family, member 30
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA panobinostat results in decreased expression of TBC1D30 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:58,665,054...58,754,427
Ensembl chr 7:58,665,054...58,754,614
|
|
G
|
Tbc1d8
|
TBC1 domain family, member 8
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of TBC1D8 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 9:49,147,109...49,257,140
Ensembl chr 9:49,147,109...49,257,118
|
|
G
|
Tbl1xr1
|
TBL1X/Y related 1
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBL1XR1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBL1XR1 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 2:106,718,811...106,857,989
Ensembl chr 2:106,730,665...106,857,989
|
|
G
|
Tbx3
|
T-box transcription factor 3
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBX3 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBX3 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171
|
|
G
|
Tc2n
|
tandem C2 domains, nuclear
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 6:126,526,006...126,622,163
Ensembl chr 6:126,526,009...126,614,215
|
|
G
|
Tdrkh
|
tudor and KH domain containing
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA panobinostat results in decreased expression of TDRKH mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:184,736,255...184,760,534
Ensembl chr 2:184,737,591...184,762,052
|
|
G
|
Tdrp
|
testis development related protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA panobinostat results in increased expression of TDRP mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:82,326,837...82,354,861
Ensembl chr16:82,314,220...82,354,861
|
|
G
|
Tenm2
|
teneurin transmembrane protein 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA panobinostat results in increased expression of TENM2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:20,984,710...22,121,001
Ensembl chr10:20,985,902...22,447,611
|
|
G
|
Tent5b
|
terminal nucleotidyltransferase 5B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA panobinostat results in increased expression of TENT5B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:150,979,238...150,986,548
Ensembl chr11:27,212,316...27,214,238 Ensembl chr 5:27,212,316...27,214,238
|
|
G
|
Tep1
|
telomerase associated protein 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of TEP1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr15:26,519,429...26,567,073
Ensembl chr15:26,519,431...26,567,073
|
|
G
|
Tes
|
testin LIM domain protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA panobinostat results in increased expression of TES mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:46,331,257...46,369,782
Ensembl chr 4:46,331,257...46,369,780
|
|
G
|
Tfap2a
|
transcription factor AP-2 alpha
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA panobinostat results in increased expression of TFAP2A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219
|
|
G
|
Tfap2b
|
transcription factor AP-2 beta
|
multiple interactions affects expression increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of TFAP2B mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA] panobinostat affects the expression of TFAP2B mRNA panobinostat results in increased expression of TFAP2B mRNA
|
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 9:29,282,703...29,312,568
Ensembl chr 9:29,282,825...29,312,568
|
|
G
|
Tfap2c
|
transcription factor AP-2 gamma
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA panobinostat results in increased expression of TFAP2C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:181,733,524...181,742,412
Ensembl chr 3:181,733,419...181,741,404
|
|
G
|
Tfcp2l1
|
transcription factor CP2-like 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA panobinostat results in increased expression of TFCP2L1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:32,286,643...32,346,671
Ensembl chr13:32,286,643...32,346,671
|
|
G
|
Tfpi
|
tissue factor pathway inhibitor
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA panobinostat results in increased expression of TFPI mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:89,939,868...89,980,742
|
|
G
|
Tfpi2
|
tissue factor pathway inhibitor 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA panobinostat results in increased expression of TFPI2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426
|
|
G
|
Tgfb1i1
|
transforming growth factor beta 1 induced transcript 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA panobinostat results in increased expression of TGFB1I1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:192,258,598...192,265,903
|
|
G
|
Tgfbi
|
transforming growth factor, beta induced
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471
|
|
G
|
Tgfbrap1
|
transforming growth factor, beta receptor associated protein 1
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TGFBRAP1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TGFBRAP1 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 9:52,813,087...52,863,441
Ensembl chr 9:52,813,087...52,863,441
|
|
G
|
Thap2
|
THAP domain containing 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:52,879,011...52,893,680
Ensembl chr 7:52,879,011...52,891,932
|
|
G
|
Thbs2
|
thrombospondin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA panobinostat results in increased expression of THBS2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:64,343,523...64,372,918
Ensembl chr 1:64,343,523...64,372,918
|
|
G
|
Thrb
|
thyroid hormone receptor beta
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA panobinostat results in increased expression of THRB mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680
|
|
G
|
Tktl1
|
transketolase-like 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:157,105,455...157,138,510
Ensembl chr X:157,105,495...157,138,503
|
|
G
|
Tle4
|
TLE family member 4, transcriptional corepressor
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA panobinostat results in decreased expression of TLE4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:221,086,250...221,222,826
Ensembl chr 1:221,086,253...221,222,826
|
|
G
|
Tmc5
|
transmembrane channel-like 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA panobinostat results in increased expression of TMC5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:182,349,102...182,433,679
Ensembl chr 1:182,355,473...182,433,679
|
|
G
|
Tmcc2
|
transmembrane and coiled-coil domain family 2
|
increases expression
|
ISO
|
Panobinostat results in increased expression of TMCC2 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr13:43,794,029...43,831,716
Ensembl chr13:46,346,177...46,383,862
|
|
G
|
Tmed5
|
transmembrane p24 trafficking protein 5
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA panobinostat results in increased expression of TMED5 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:1,752,857...1,763,990
Ensembl chr14:1,752,745...1,773,389
|
|
G
|
Tmem125
|
transmembrane protein 125
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA panobinostat results in increased expression of TMEM125 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:137,348,545...137,349,949
Ensembl chr 5:137,345,202...137,351,952
|
|
G
|
Tmem144
|
transmembrane protein 144
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA panobinostat results in increased expression of TMEM144 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:164,960,649...164,993,562
Ensembl chr 2:167,258,789...167,290,902
|
|
G
|
Tmem154
|
transmembrane protein 154
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA panobinostat results in increased expression of TMEM154 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:172,313,290...172,352,939
Ensembl chr 2:172,313,240...172,361,723
|
|
G
|
Tmem163
|
transmembrane protein 163
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA panobinostat results in decreased expression of TMEM163 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:41,520,595...41,693,938
Ensembl chr13:41,520,359...41,693,938
|
|
G
|
Tmem169
|
transmembrane protein 169
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA panobinostat results in decreased expression of TMEM169 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:81,375,854...81,399,970
|
|
G
|
Tmem170b
|
transmembrane protein 170B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA panobinostat results in decreased expression of TMEM170B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:23,336,914...23,375,707
Ensembl chr17:23,343,017...23,375,519
|
|
G
|
Tmem178a
|
transmembrane protein 178A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA panobinostat results in decreased expression of TMEM178A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:19,756,919...19,815,961
Ensembl chr 6:19,756,920...19,815,839
|
|
G
|
Tmem18
|
transmembrane protein 18
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA panobinostat results in decreased expression of TMEM18 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:52,934,419...52,941,868
Ensembl chr 6:52,934,419...52,941,866
|
|
G
|
Tmem218
|
transmembrane protein 218
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of TMEM218 mRNA
|
CTD |
PMID:26272509 |
|
NCBI chr 8:45,113,368...45,128,739
Ensembl chr 8:45,113,427...45,129,152
|
|
G
|
Tmem30b
|
transmembrane protein 30B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA panobinostat results in increased expression of TMEM30B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:97,987,471...97,990,546
Ensembl chr 6:97,987,130...97,991,170
|
|
G
|
Tmem64
|
transmembrane protein 64
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA panobinostat results in increased expression of TMEM64 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:33,495,992...33,542,390
Ensembl chr 5:33,496,032...33,542,389
|
|
G
|
Tmem74
|
transmembrane protein 74
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA panobinostat results in decreased expression of TMEM74 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:76,814,000...76,822,633
Ensembl chr 7:76,813,212...76,822,925
|
|
G
|
Tmem88
|
transmembrane protein 88
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA panobinostat results in decreased expression of TMEM88 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:54,617,554...54,619,309
Ensembl chr10:54,617,630...54,619,438
|
|
G
|
Tmod2
|
tropomodulin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA panobinostat results in increased expression of TMOD2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,197,222...85,250,627
Ensembl chr 8:85,196,226...85,246,371
|
|
G
|
Tmprss11e
|
transmembrane serine protease 11E
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:21,638,418...21,683,029
Ensembl chr14:21,638,418...21,683,029
|
|
G
|
Tmt1a
|
thiol methyltransferase 1A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 7:133,330,141...133,377,172
Ensembl chr 7:133,330,447...133,338,959
|
|
G
|
Tnfaip3
|
TNF alpha induced protein 3
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of TNFAIP3 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979
|
|
G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA panobinostat results in increased expression of TNFRSF11B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075
|
|
G
|
Tnfrsf12a
|
TNF receptor superfamily member 12A
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA panobinostat results in increased expression of TNFRSF12A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704
|
|
G
|
Tnfrsf19
|
TNF receptor superfamily member 19
|
increases expression
|
ISO
|
Panobinostat results in increased expression of TNFRSF19 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of TNFSF10 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA panobinostat results in increased expression of TNFSF11 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Tnfsf9
|
TNF superfamily member 9
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339
|
|
G
|
Tnik
|
TRAF2 and NCK interacting kinase
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA panobinostat results in increased expression of TNIK mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:113,112,937...113,511,341
Ensembl chr 2:113,112,938...113,511,339
|
|
G
|
Tnn
|
tenascin N
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA panobinostat results in increased expression of TNN mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:74,852,586...74,919,789
Ensembl chr13:74,852,586...74,919,789
|
|
G
|
Tnrc6b
|
trinucleotide repeat containing adaptor 6B
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of TNRC6B mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 7:114,132,574...114,350,010
Ensembl chr 7:114,132,573...114,342,973
|
|
G
|
Tox
|
thymocyte selection-associated high mobility group box
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA panobinostat results in increased expression of TOX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:24,672,487...24,968,754
Ensembl chr 5:24,672,487...24,968,754
|
|
G
|
Tox2
|
TOX high mobility group box family member 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA panobinostat results in decreased expression of TOX2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:172,272,718...172,400,235
Ensembl chr 3:172,272,736...172,400,233
|
|
G
|
Tox3
|
TOX high mobility group box family member 3
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA panobinostat results in decreased expression of TOX3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:32,820,957...32,929,776
Ensembl chr19:32,820,977...32,929,776
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases acetylation
|
ISO
|
[panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein panobinostat results in increased acetylation of TP53 protein
|
CTD |
PMID:23681230 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp63
|
tumor protein p63
|
increases expression
|
ISO
|
panobinostat results in increased expression of TP63 protein alternative form
|
CTD |
PMID:20043870 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177
|
|
G
|
Tpbg
|
trophoblast glycoprotein
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 8:95,673,993...95,677,364
Ensembl chr 8:95,629,267...95,678,394
|
|
G
|
Tpd52l1
|
TPD52 like 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA panobinostat results in increased expression of TPD52L1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:27,991,131...28,110,158
|
|
G
|
Trabd2b
|
TraB domain containing 2B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA panobinostat results in increased expression of TRABD2B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:133,178,014...133,395,740
Ensembl chr 5:133,178,302...133,441,812
|
|
G
|
Trim14
|
tripartite motif-containing 14
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA panobinostat results in increased expression of TRIM14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:65,596,149...65,620,434
Ensembl chr 5:65,596,149...65,620,434
|
|
G
|
Trim38
|
tripartite motif containing 38
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA panobinostat results in increased expression of TRIM38 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:41,774,419...41,787,709
|
|
G
|
Trim6
|
tripartite motif containing 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA panobinostat results in increased expression of TRIM6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:168,095,619...168,108,809
Ensembl chr 1:168,095,564...168,109,719
|
|
G
|
Trim69
|
tripartite motif-containing 69
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA panobinostat results in increased expression of TRIM69 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:129,565,060...129,585,629
Ensembl chr 3:129,564,934...129,585,629
|
|
G
|
Trim8
|
tripartite motif-containing 8
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TRIM8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TRIM8 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 1:255,311,039...255,325,937
Ensembl chr 1:255,310,457...255,325,937
|
|
G
|
Trim9
|
tripartite motif-containing 9
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA panobinostat results in increased expression of TRIM9 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:94,492,789...94,592,597
Ensembl chr 6:94,493,268...94,592,551
|
|
G
|
Trnp1
|
TMF1-regulated nuclear protein 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA panobinostat results in increased expression of TRNP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:150,990,312...150,997,148
Ensembl chr 5:150,989,973...150,997,277
|
|
G
|
Trpc2
|
transient receptor potential cation channel subfamily C member 2
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with Panobinostat] affects the expression of TRPC2 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:165,871,991...165,885,339
Ensembl chr 1:165,857,557...165,885,055
|
|
G
|
Trpc4
|
transient receptor potential cation channel, subfamily C, member 4
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA panobinostat results in decreased expression of TRPC4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:140,457,841...140,629,556
Ensembl chr 2:140,458,296...140,626,969
|
|
G
|
Trpc6
|
transient receptor potential cation channel, subfamily C, member 6
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA panobinostat results in increased expression of TRPC6 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304
|
|
G
|
Trps1
|
transcriptional repressor GATA binding 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA panobinostat results in increased expression of TRPS1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:83,806,121...84,032,609
Ensembl chr 7:83,811,497...84,031,786
|
|
G
|
Tshz2
|
teashirt zinc finger homeobox 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:178,824,221...179,271,151
Ensembl chr 3:178,824,994...179,269,641
|
|
G
|
Tspo
|
translocator protein
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA panobinostat results in increased expression of TSPO mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:116,600,214...116,610,461
Ensembl chr 7:116,600,210...116,610,460
|
|
G
|
Tspoap1
|
TSPO associated protein 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of TSPOAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:73,053,414...73,083,640
Ensembl chr10:73,058,354...73,083,640
|
|
G
|
Ttc29
|
tetratricopeptide repeat domain 29
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA panobinostat results in increased expression of TTC29 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:46,436,526...46,654,891
Ensembl chr19:46,424,935...46,654,870
|
|
G
|
Ttll6
|
tubulin tyrosine ligase like 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:81,081,985...81,118,009
Ensembl chr10:81,579,178...81,623,919
|
|
G
|
Tuba1a
|
tubulin, alpha 1A
|
decreases expression
|
ISO
|
panobinostat results in decreased expression of TUBA1A mRNA
|
CTD |
PMID:27015953 |
|
NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035
|
|
G
|
Tubb2a
|
tubulin, beta 2A class IIa
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA panobinostat results in increased expression of TUBB2A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838
|
|
G
|
Tulp4
|
TUB like protein 4
|
increases expression
|
ISO
|
Panobinostat results in increased expression of TULP4 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 1:49,082,492...49,218,262
Ensembl chr 1:49,087,886...49,218,250
|
|
G
|
Tvp23a
|
trans-golgi network vesicle protein 23 homolog A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:5,227,198...5,263,185
Ensembl chr10:5,734,100...5,769,998
|
|
G
|
Twist1
|
twist family bHLH transcription factor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA panobinostat results in increased expression of TWIST1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965
|
|
G
|
Ugt2b34l1
|
UDP glucuronosyltransferase 2 family, polypeptide B34 like 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr14:21,500,948...21,524,095
Ensembl chr14:21,501,091...21,522,265
|
|
G
|
Ugt3a1
|
UDP glycosyltransferase family 3 member A1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:60,062,257...60,077,354
Ensembl chr 2:60,061,775...60,077,354
|
|
G
|
Ugt8
|
UDP glycosyltransferase 8
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA panobinostat results in increased expression of UGT8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:216,938,884...217,007,167
Ensembl chr 2:216,938,990...217,007,167
|
|
G
|
Unc5a
|
unc-5 netrin receptor A
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of UNC5A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:9,614,841...9,670,558
Ensembl chr17:9,620,005...9,676,140
|
|
G
|
Unc5c
|
unc-5 netrin receptor C
|
multiple interactions affects expression increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of UNC5C mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of UNC5C mRNA] panobinostat affects the expression of UNC5C mRNA panobinostat results in increased expression of UNC5C mRNA
|
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 2:232,854,352...233,208,482
Ensembl chr 2:232,846,262...233,208,482
|
|
G
|
Uqcc2
|
ubiquinol-cytochrome c reductase complex assembly factor 2
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA panobinostat results in decreased expression of UQCC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:5,204,682...5,217,080
Ensembl chr17:12,088,037...12,088,606 Ensembl chr20:12,088,037...12,088,606
|
|
G
|
Usp28
|
ubiquitin specific peptidase 28
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA panobinostat results in increased expression of USP28 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:58,222,258...58,282,711
Ensembl chr 8:58,222,220...58,282,750
|
|
G
|
Usp43
|
ubiquitin specific peptidase 43
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:53,047,368...53,110,099
Ensembl chr10:53,048,158...53,110,180
|
|
G
|
Usp49
|
ubiquitin specific peptidase 49
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA panobinostat results in decreased expression of USP49 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:20,803,177...20,867,681
Ensembl chr 9:20,804,921...20,863,667
|
|
G
|
Ust
|
uronyl-2-sulfotransferase
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of UST mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 1:4,487,316...4,782,579
Ensembl chr 1:4,489,925...4,782,356
|
|
G
|
Utf1
|
undifferentiated embryonic cell transcription factor 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA panobinostat results in increased expression of UTF1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:194,740,339...194,741,465
Ensembl chr 1:204,169,954...204,171,080
|
|
G
|
Vamp7
|
vesicle-associated membrane protein 7
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of VAMP7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:21,842,206...21,958,556
Ensembl chr12:21,842,228...21,958,552
|
|
G
|
Vamp8
|
vesicle-associated membrane protein 8
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of VAMP8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:106,000,570...106,011,081
Ensembl chr 4:106,000,570...106,011,073
|
|
G
|
Vapa
|
VAMP associated protein A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA panobinostat results in decreased expression of VAPA mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:112,624,791...112,654,731
Ensembl chr 9:112,624,794...112,654,731
|
|
G
|
Vash2
|
vasohibin 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA panobinostat results in increased expression of VASH2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:105,060,857...105,092,325
Ensembl chr13:105,060,857...105,092,275
|
|
G
|
Ventx
|
VENT homeobox
|
increases expression multiple interactions
|
ISO
|
Panobinostat results in increased expression of VENTX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:90,707,273...90,708,315
Ensembl chr X:90,706,748...90,708,555
|
|
G
|
Veph1
|
ventricular zone expressed PH domain-containing 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA panobinostat results in increased expression of VEPH1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:150,291,379...150,537,491
Ensembl chr 2:152,601,680...152,847,318
|
|
G
|
Vgll1
|
vestigial-like family member 1
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA panobinostat results in increased expression of VGLL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:140,016,938...140,036,348
|
|
G
|
Vgll3
|
vestigial-like family member 3
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of VGLL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:3,642,993...3,692,590
Ensembl chr11:17,089,597...17,138,937
|
|
G
|
Wdr72
|
WD repeat domain 72
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA panobinostat results in increased expression of WDR72 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:83,718,897...83,902,128
Ensembl chr 8:83,718,914...83,900,286
|
|
G
|
Wfdc17
|
WAP four-disulfide core domain 17
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA panobinostat results in decreased expression of KAL1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:69,059,451...69,060,298
|
|
G
|
Wfdc2
|
WAP four-disulfide core domain 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA panobinostat results in increased expression of WFDC2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:173,706,091...173,735,055
Ensembl chr 3:173,706,460...173,712,161
|
|
G
|
Wls
|
Wnt ligand secretion mediator
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 2:251,590,653...251,705,991
Ensembl chr 2:251,590,614...251,706,380
|
|
G
|
Wnt10b
|
Wnt family member 10B
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA panobinostat results in increased expression of WNT10B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:131,801,046...131,806,850
Ensembl chr 7:131,801,046...131,806,850
|
|
G
|
Wnt3
|
Wnt family member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA Panobinostat results in increased expression of WNT3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195
|
|
G
|
Wnt4
|
Wnt family member 4
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA panobinostat results in increased expression of WNT4 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128
|
|
G
|
Wnt5a
|
Wnt family member 5A
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA panobinostat results in decreased expression of WNT5A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860
|
|
G
|
Wnt5b
|
Wnt family member 5B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA panobinostat results in decreased expression of WNT5B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681
|
|
G
|
Wnt6
|
Wnt family member 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 9:83,778,552...83,792,186
Ensembl chr 9:83,778,552...83,792,186
|
|
G
|
Wnt8a
|
Wnt family member 8A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr18:26,411,833...26,417,426
Ensembl chr18:26,411,833...26,417,426
|
|
G
|
Wwc1
|
WW and C2 domain containing 1
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of WWC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:20,804,173...20,958,437
Ensembl chr10:20,799,237...20,958,437
|
|
G
|
Xcl1
|
X-C motif chemokine ligand 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of XCL1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr13:79,781,784...79,785,440
Ensembl chr13:79,781,784...79,785,440
|
|
G
|
Xkr4
|
XK related 4
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 5:20,694,433...21,095,350
Ensembl chr 5:20,693,966...21,080,579
|
|
G
|
Xkrx
|
XK related, X-linked
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr X:101,634,438...101,733,814
Ensembl chr X:101,635,283...101,646,461
|
|
G
|
Yap1
|
Yes1 associated transcriptional regulator
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of YAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437
|
|
G
|
Ypel1
|
yippee-like 1
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr11:97,426,012...97,440,646
|
|
G
|
Zbtb1
|
zinc finger and BTB domain containing 1
|
decreases expression
|
ISO
|
Panobinostat results in decreased expression of ZBTB1 mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr 6:100,832,506...100,864,019
Ensembl chr 6:100,838,714...100,852,643
|
|
G
|
Zbtb16
|
zinc finger and BTB domain containing 16
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA panobinostat results in decreased expression of ZBTB16 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:57,891,081...58,073,507
|
|
G
|
Zc3h12c
|
zinc finger CCCH type containing 12C
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ZC3H12C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:61,340,446...61,404,932
Ensembl chr 8:61,345,271...61,400,610
|
|
G
|
Zc3h6
|
zinc finger CCCH type containing 6
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:116,203,466...116,254,186
Ensembl chr 3:136,657,414...136,706,504
|
|
G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ZEB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
G
|
Zfp14
|
ZFP14 zinc finger protein
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA panobinostat results in decreased expression of ZFP14 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:94,396,055...94,413,338
Ensembl chr 1:94,396,057...94,413,534
|
|
G
|
Zfp2
|
zinc finger protein 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:35,701,303...35,729,861
Ensembl chr10:35,702,151...35,730,108
|
|
G
|
Zfp280c
|
zinc finger protein 280C
|
increases expression
|
ISO
|
Panobinostat results in increased expression of ZNF280C mRNA
|
CTD |
PMID:33770205 |
|
NCBI chr X:132,594,279...132,685,548
Ensembl chr X:132,594,292...132,685,841
|
|
G
|
Zfp287
|
zinc finger protein 287
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr10:47,896,517...47,914,860
Ensembl chr10:47,896,517...47,914,950
|
|
G
|
Zfp36l2
|
zinc finger protein 36, C3H type-like 2
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA panobinostat results in increased expression of ZFP36L2 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653
|
|
G
|
Zfp385b
|
zinc finger protein 385B
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA panobinostat results in decreased expression of ZNF385B mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:82,762,387...83,140,856
Ensembl chr 3:82,762,387...83,084,615
|
|
G
|
Zfp385d
|
zinc finger protein 385D
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA panobinostat results in decreased expression of ZNF385D mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:7,473,431...7,854,364
Ensembl chr15:7,473,435...8,504,582
|
|
G
|
Zfp386
|
zinc finger protein 386 (Kruppel-like)
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA panobinostat results in decreased expression of ZNF519 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:143,109,563...143,124,266
Ensembl chr 6:143,109,610...143,127,027
|
|
G
|
Zfp42
|
zinc finger protein 42
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ZFP42 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:55,568,903...55,577,883
Ensembl chr16:55,568,093...55,578,170 Ensembl chr 4:55,568,093...55,578,170
|
|
G
|
Zfp46
|
zinc finger protein 46
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA panobinostat results in decreased expression of ZNF436 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:153,802,887...153,813,388
Ensembl chr 5:153,802,834...153,812,941
|
|
G
|
Zfp462
|
zinc finger protein 462
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF462 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF462 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 5:74,465,383...74,606,020
Ensembl chr 5:74,468,643...74,606,020
|
|
G
|
Zfp483
|
zinc finger protein 483
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA panobinostat results in decreased expression of ZNF483 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:73,763,201...73,780,511
Ensembl chr 5:78,558,304...78,575,552
|
|
G
|
Zfp503
|
zinc finger protein 503
|
multiple interactions decreases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA panobinostat results in decreased expression of ZNF503 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:2,362,450...2,366,238
Ensembl chr15:2,362,427...2,366,238
|
|
G
|
Zfp521
|
zinc finger protein 521
|
decreases expression multiple interactions
|
ISO
|
panobinostat results in decreased expression of ZNF521 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:5,050,297...5,343,188
Ensembl chr18:5,056,236...5,343,054
|
|
G
|
Zfp804a
|
zinc finger protein 804A
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr 3:87,440,496...87,670,872
Ensembl chr 3:87,197,582...87,670,869
|
|
G
|
Zfp827
|
zinc finger protein 827
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF827 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF827 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430
|
|
G
|
Zic1
|
Zic family member 1
|
multiple interactions
|
ISO
|
[Cisplatin co-treated with panobinostat] affects the expression of ZIC1 mRNA
|
CTD |
PMID:21791302 |
|
NCBI chr 8:100,785,282...100,797,716
Ensembl chr 8:100,787,789...100,792,427
|
|
G
|
Zic3
|
Zic family member 3
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA panobinostat results in increased expression of ZIC3 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:141,159,623...141,165,587
Ensembl chr X:141,149,594...141,170,464
|
|
G
|
Zmym2
|
zinc finger MYM-type containing 2
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr15:35,151,356...35,224,528
Ensembl chr15:35,127,994...35,224,941
|
|
G
|
Zmynd8
|
zinc finger, MYND-type containing 8
|
multiple interactions affects expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZMYND8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZMYND8 mRNA]
|
CTD |
PMID:26733615 |
|
NCBI chr 3:174,948,162...175,061,382
Ensembl chr 3:174,948,537...175,061,571
|
|
G
|
Znf750
|
zinc finger protein 750
|
multiple interactions increases expression
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA panobinostat results in increased expression of ZNF750 mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:107,270,926...107,279,904
Ensembl chr10:107,270,763...107,279,300
|
|
G
|
Zranb3
|
zinc finger RANBP2-type containing 3
|
multiple interactions
|
ISO
|
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA
|
CTD |
PMID:27188386 |
|
NCBI chr13:41,993,110...42,148,298
Ensembl chr13:41,992,922...42,148,274
|
|
G
|
Zyg11a
|
zyg-11 family member A, cell cycle regulator
|
increases expression multiple interactions
|
ISO
|
panobinostat results in increased expression of ZYG11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA
|
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:128,163,732...128,202,462
Ensembl chr 5:128,164,884...128,202,481
|
|